| ‹v—Æ•Ä‘åŠw| ˆćŠw•”| S‘ŸEŒŒŠĒ“ą‰Č| ¬Ž™‰Č| ŠO‰Č| ‹v—Æ•Ä‘åŠw•a‰@|

toiawase
  • §830-0011
  • •Ÿ‰ŖŒ§‹v—Æ•ÄŽsˆ®’¬67
  • TEL: 0942-35-3800
  • FAX: 0942-31-7707 mailto
‘ę33‰ń“ś–{‚ŒŒˆ³Šw‰ļ‘‰ļ
‚Š‚ē‚ß‚«‚Ę‚«‚ß‚«ƒTƒCƒGƒ“ƒX

Œ¤‹†‹ĘŃ > 2007”N

’˜‘@ ‰p•¶˜_•¶ ˜a•¶˜_•¶ ‘ŪŠw‰ļ ‘“ąŠw‰ļ Ē—į•ń ‘ą Œ°² Œ¤‹†•¬‹ą “Į‹–

’˜‘

  1. Ā–ö¬–¾FŠ“õ«S“ą–Œ‰Š‚ĢŽ”—Ɛķ—ŖA ‹¹•”ŠO‰ČUp to DateA‘ę60‰ń“ś–{‹¹•”ŠO‰ČŠw‰ļ’芜ŠwpW‰ļPostgraduate CourseƒeƒLƒXƒgF23-30,2007
  2. Ā–ö¬–¾A•Ÿ‰iŽüŽiF‘m–X•Ł‹·óĒAS‘Ÿ•Ł–ŒĒ‚ĢŠO‰Č?‘ę‚R”Å?F280-298,2007
  3. Ā–ö¬–¾F‘m–X•Ł’uŠ·p (MVR)AS‘Ÿ•Ł–ŒĒ‚ĢŠO‰Č?‘ę‚R”Å?F400-415,2007
  4. ŒÜ\—’—²C¼Ī–LŽŸ˜YC{“cŒ›Ž”Cˆäć’‰•vC–Ų’ƏƒŽqŠÄ–óFƒnƒŠƒGƒbƒgƒŒ[ƒ“ƒnƒ“ƒhƒuƒbƒN|ƒWƒ‡ƒ“ƒYEƒzƒvƒLƒ“ƒX•a‰@¬Ž™‰ČƒŒƒWƒfƒ“ƒgƒ}ƒjƒ…ƒAƒ‹A MEDSiFś@-xviii,2007
  5. {“cŒ›Ž”–óAKelly KAGajewskiFS‘Ÿ•a.ƒnƒŠƒGƒbƒgƒŒ[ƒ“ƒnƒ“ƒhƒuƒbƒN|ƒWƒ‡ƒ“ƒYEƒzƒvƒLƒ“ƒX•a‰@¬Ž™‰ČƒŒƒWƒfƒ“ƒgƒ}ƒjƒ…ƒAƒ‹AMEDSiF143-185,2007
  6. {“cŒ›Ž”–óAJanson RobertsonFŒŒ‰t¶‰»Šw‚Ę‘Ģ‰t.ƒnƒŠƒGƒbƒgƒŒ[ƒ“ƒnƒ“ƒhƒuƒbƒN|ƒWƒ‡ƒ“ƒYEƒzƒvƒLƒ“ƒX•a‰@¬Ž™‰ČƒŒƒWƒfƒ“ƒgƒ}ƒjƒ…ƒAƒ‹AMEDSiF573-585,2007
  7. {“cŒ›Ž”CH“”‰ĆŒöC›Œ“—mŽqCĪˆä³_C¼Ī–LŽŸ˜YFŠ„“®–¬įŽ‚É‘Ī‚·‚éRŒŒš—Ć–@A“ś–{—Տ°F66(2)F355-359,2008
  8. ‘O–ģ‘׎÷FEBM‚ÉŠī‚Ć‚­‘ŁŽ™S‘Ÿ•a‚Ģf’fŽ”—ƁF‘Ł“ąŽ”—Ć‚Ģ‰Ā”\«‚ĶH EBM¬Ž™Ž¾Š³‚ĢŽ”—ƁF62-66,2007-2008
  9. ‘O–ģ‘׎÷C_“c—mC“”–ģ_Fę“V«•s®–¬ię“V«S–[‘e“®Cę“V«ćŽŗ«•p”Cę“V«SŽŗ•p”Cę“V«Š®‘S–[ŽŗƒuƒƒbƒNj“ś–{—Տ°@zŠĀŠķĒŒóŒQi‘ę‚Q”ŁjF408-412
  10. ‘O–ģ‘׎÷CL£²ŽqC_ŒĖ‘¾˜YF‘ŁŽ™•s®–¬A“ś–{—Տ°@zŠĀŠķĒŒóŒQi‘ę‚Q”ŁjF419-424
  11. ‘O–ģ‘׎÷CœA£²ŽqF‘ŁŽ™EV¶Ž™ˆŁķ‚ĢŽ”—Ć‚Ę‚»‚Ģ—\ŒćA‘ŁŽ™•s®–¬DŽY•wl‰Č‚ĢŽĄŪF56:875-881,2007
  12. ‘O–ģ‘׎÷FzŠĀŠķŽ¾Š³‚ĢŠī‘b’mŽÆ‚ĘŠĒ—Aę“V«SŽ¾Š³‚Ģf’f‚ĘŽ”—ƁANeonatal Care@F20:18-3,2007
  13. Kato H, Takahashi K. Kawasaki's diseaseFEdited by Gene V.Ball, S Louis Bridges, Jr. Vasculitis second editionF373-389,2007-2008
  14. Abe R, Yamagishi S: Novel therapeutic strategy for the treatment of malignant melanoma. Progress in Skin Cancer Research (Horizons in Cancer Research, Volume 30) V.L. Heinz eds., Nova Science, NY, Chapter I: 1-26, 2007
  15. b”ć‹vŽj•ŅWFŠÅŒģŽt‘‰ĘŽŽŒ±@Žć“_Ž•žƒTƒuƒm[ƒgŠī‘bˆćŠw•Ņ2007”N“x”ŁA ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽŠA“Œ‹žF2007
  16. ‰Ŗ@’¼Ž÷A”ņ@•×F‡W.”ģ‘åŒ^S‹ŲĒ@Œo‰ß‚Ę—\Œć.@V–Ś‚Å‚Ż‚ézŠĀŠķ•aƒVƒŠ[ƒY15@S‹ŲĒA¼X@ŗ•ŅAƒƒWƒJƒ‹ƒrƒ…[ŽŠA“Œ‹žF164-168,2007.3
  17. ¼‰ŖG—mA”ņ@•×FRŽ_‰»–ņ‚ĢŒ»ó‚ʍ”Œć‚ĢŠś‘Ņ42.ACE‘jŠQ–ņ/AT1Žó—e‘ĢhR–ņ.@Ž_‰»ƒXƒgƒŒƒX‚ʐSŒŒŠĒ•aA‰”ŽRŒõGA“”“c•q˜Y•ŅA“ś–{ˆćŠwo”ŁA “Œ‹žF243-248,2007.4
  18. b”ć‹vŽjFLate-Breaking Basic Session . ISHƒnƒCƒ‰ƒCƒgA]“”ˆū®A‹e’rŒ’ŽŸ˜YA‘ė‰ŗCˆźA’|‰ŗ@²A“”“c•q˜YA¼‰Ŗ”ŽŗAŽO‰YK—Y•ŅAƒƒfƒBƒJƒ‹EƒWƒƒ[ƒiƒ‹ŽŠA“Œ‹žF130-132,2007
  19. ‘«’B@ŽõF“ĮWu‚ķ‚Ŗ‘‚É‚Ø‚Æ‚ézŠĀŠķ‰uŠwŒ¤‹†‚ĢƒRƒz[ƒgv“cŽåŠŪŒ¤‹†.@CARDIAC PRACTICEA”ņ@•×•ŅAƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽŠA“Œ‹žF18(2)F63-66,2007
  20. ‘å“ą“c¹’¼A”ņ@•×F‹}«¶S•s‘S.@”“ś‚Ģˆ•ūi‰ü’ł‘ę4”ŁjA‚‹vŽj–›A…“‡@—TŠÄCA‰Y•”»•vA‘å“c@Œ’AŠ™’J’¼”VA“‡“c˜aKA›–ģŒ’‘¾˜YA•’J—Y“ń•ŅA“ģ]“°A“Œ‹žF147-148,2007.4
  21. ‘å“ą“c¹’¼A”ņ@•×F–«‚¤‚ĮŒŒ«S•s‘S.@”“ś‚Ģˆ•ūi‰ü’ł‘ę4”ŁjA‚‹vŽj–›A…“‡@—TŠÄCA‰Y•”»•vA‘å“c@Œ’AŠ™’J’¼”VA“‡“c˜aKA›–ģŒ’‘¾˜YA•’J—Y“ń•ŅA“ģ]“°A“Œ‹žF149-150,2007.4
  22. ¼‰ŖG—mFŒŒŠĒ“ą”ē‹@”\‚Ģ‘Ŗ’č–@.@ŒŒŠĒ“ą”ē×–E‚š‚ß‚®‚鎾Š³A“‡“c˜aK•ŅA ^‹»ŒšˆÕˆć‘o”Å•”A“Œ‹žF81-92,2007
  23. Œ““c°mAb”ć‹vŽjFONE POINT ADVICE ˆā“`Žqf’f‚šf—Ć‚É‚Ē‚¤Šˆ‚©‚·‚©. VES‘Ÿ•af—Ćƒvƒ‰ƒNƒeƒBƒX10@S‹ŲĒ‚šŽÆ‚éEf‚éEŽ”‚·Aˆé•”ŒõĶA¼č‰v“æ•ŅA •¶Œõ“°A“Œ‹žF37,2007
  24. ŒĆ‰ź‹`‘„FŠT”O‚Ę’č‹`. ”ģ‘åŒ^S‹ŲĒƒnƒ“ƒhƒuƒbƒNAŒĆ‰ź‹`‘„•ŅA“ś–{ˆćŽ–V•ńŽŠA“Œ‹žF2-7,2007
  25. ŒĆ‰ź‹`‘„F‰uŠw. ”ģ‘åŒ^S‹ŲĒƒnƒ“ƒhƒuƒbƒNAŒĆ‰ź‹`‘„•ŅA“ś–{ˆćŽ–V•ńŽŠA “Œ‹žF8-12,2007 ‹g“c“TŽqA’r“c‹v—YF‰^“®•‰‰×ŽŽŒ±. ”ģ‘åŒ^S‹ŲĒƒnƒ“ƒhƒuƒbƒNAŒĆ‰ź‹`‘„•ŅA “ś–{ˆćŽ–V•ńŽŠA“Œ‹žF129-138,2007
  26. ŒĆ‰ź‹`‘„FSė•””ģ‘åŒ^S‹ŲĒ‚Ģ—\Œć‚ĘŽ©‘R—š. ”ģ‘åŒ^S‹ŲĒƒnƒ“ƒhƒuƒbƒNAŒĆ‰ź‹`‘„•ŅA“ś–{ˆćŽ–V•ńŽŠA“Œ‹žF215-223,2007
  27. ‰Į“”GŽiA’r“c‹v—YA”ņ@•×FŽ”—Ɛķ—Ŗ‚Ģ—§‚Ä•ū‚ʐ¶ŠˆŽw“±. ”ģ‘åŒ^S‹ŲĒƒnƒ“ƒhƒuƒbƒNAŒĆ‰ź‹`‘„•ŅA“ś–{ˆćŽ–V•ńŽŠA“Œ‹žF234-243,2007
  28. ‘ź@Œ’AŒĆ‰ź‹`‘„FĒšĒ‚Ģ—\–h. ”ģ‘åŒ^S‹ŲĒƒnƒ“ƒhƒuƒbƒNAŒĆ‰ź‹`‘„•ŅA“ś–{ˆćŽ–V•ńŽŠA“Œ‹žF254-258,2007

‰p•¶˜_•¶

  1. S.Aoyagi, T.Okazaki, S.Fukunaga, T.UedaFConcomitant Traumatic Aortic Valve and Coronary Artery Injury. Ann Thorac SurgF289-291,2007
  2. E.Tayama, T.Ueda, T.Shojima K.Akasu T.Oda, S.Fukunaga, H.Akashi, S.AoyagiF Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interactive CardioVascular and Thoracic SurgeryF715-719,2007
  3. S.Aoyagi, H.Hori, K.Yoshikawa, K.Arinaga, S.FukunagaFMid-Term Results of Valve Replacement with the ATS Valve : A Seven-Year Follow UP. J. Heart Valve DisF267-274,2007
  4. S.Aoyagi, S.Fukunaga, E.Tayama, T.YoshidaFExtraanatomic Aortic Bypass for Repair of Aortic Coarctation. J Card SurgF436-439,2007
  5. S.Hiromatsu, N.Egawa, Y.Hosokawa, K.Ishihara, H.Yokokura, A.Tanaka, S.AoyagiFA shorter skin incision technique for the repair of infrarenal abdominal aortic aneurysms. Surg TodayF97-102,2007
  6. H.Yokokura, S.Hiromatsu, H.akashi, S.Kato, S.AoyagiFEffects of calcium ahannel blocker azelnidipine on experimentalabdominal aortic aneurysms. Surg TodayF468-473,2007
  7. Suda K, Matsumura M, Nishimura KFEmergency stent implantation into obstructed inferior caval vein in a patient with heterotaxy and anomalous hepatic venous drainage. Pediatrics InternationalF49(2):251-252,2007
  8. Muta H, Ishii M, Iemura M, Suda K, Nakamura Y, Matsuishi TFEffect of revision of Japanese diagnostic criterion for fever in Kawasaki disease on treatment and cardiovascular outcome. Circulation JournalF71(11):1791-1793,2007
  9. Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, Egashira K, Matsuishi T, Kai M, Kataoka Y, Kuwano M, Imaizumi T.FMutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun.F2008 Jan 11;365(2):279-84. Epub 2007 Nov 6
  10. Kasahara M, Kai H, Okamura T, Wada T, Suda K, Imaizumi T, Sagawa kFUsefulness of higt-concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high-hematocrit value. Thrombosis researchF(2007 in press)
  11. Bigras JL, Suda K, Nagib S. Dahdah, Fouron JCFCardiovascular evaluation of fetal anemia due to alloimmunization. Fetal Diagnosis and TherapyF(2007 in press)
  12. Suda K, Matsumura M, Miyanishi SFIntermittent heparin infusion in small children with ischemic heart disease caused by Kawasaki disease. Int J CardiolF(2007 in press)
  13. Kanahara M, Kai H, Toyomasu K, Yoshida T, Hiraki T, Sagawa K, Imaizumi T: Characteristic features of QRST integral mapping in patients with high-risk Brugada syndrome. Circ J 71 (1):63-69,2007.1
  14. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y, Imaizumi T: Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. - An epidemiological study - Atherosclerosis 191(1):206-210,2007.3
  15. Aicher A, Rentsch M, Sasaki K, Ellwart JW, Fandrich F, Siebert R, Cooke JP, Dimmeler S, Heeschen C: Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 100(4): 581-589,2007.3
  16. Koga M, Kai H, Yasukawa H, Kato S, Yamamoto T, Kawai Y, Kusaba K, Seki Y, Kai M, Egashira K, Kataoka Y, Imaizumi T: Postnatal blocking of interferon-ƒĮ function prevented atherosclerotic plaque formation in apolipoprotein E-knockout mice. Hypertens Res 30(3):259-267,2007.3
  17. Kusaba K, Kai H, Koga M, Takayama N, Ikeda A, Yasukawa H, Seki Y, Egashira K, Imaizumi T: Inhibition of intrinsic interferon-ƒĮ function prevents neointima formation after balloon injury. Hypertension 49(4):909-915,2007.4
  18. Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T: Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 49(14):1533-1539,2007.4
  19. Yamagishi S, Matsuoka H, Kitano S, Hibi N, Jinnouchi Y, Umei H, Iida S, Takenaka K, Matsui T, Nakamura K, Imaizumi T: Elevated circulating oxidized LDL levels in Japanese subjects with the metabolic syndrome. Int J Cardiol 118(2):270-272,2007.5
  20. Haramaki N, Ikeda H, Takenaka K, Katoh A, Sugano R, Yamagishi S, Matsuoka H, Imaizumi T: Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: Possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 27(6):1471-1477,2007.6
  21. Hino A, Adachi H, Enomoto M, Furuki K, Shigetoh Y, Ohtsuka M, Kumagae S, Hirai Y, Jalaldin A, Satoh A, Imaizumi T: Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome. - An epidemiological study in a general Japanese population. Diabetes Res Clin Pract 76(3):383-389,2007.6
  22. Saito Y, Sasaki K, Katsuda Y, Murohara T, Takeshita Y, Okazaki T, Arima K, Katsuki Y, Shintani S, Shimada T, Akashi H, Ikeda H, Imaizumi T: Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. Circ J 71(8):1187-1192,2007.8
  23. Koga M, Kai H, Yasukawa H, Yamamoto T, Kawai Y, Kato S, Kusaba K, Kai M, Egashira K, Kataoka Y, Imaizumi T: Inhibition of progression and stabilization of plaques by postnatal interferon-ƒĮ function blocking in ApoE-knockout mice. Circ Res 101(4):348-356,2007.8
  24. Tahara N, Kai H, Nakaura H, Mizoguchi M, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T: The prevalence of inflammation in carotid atherosclerosis-analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J 28(18):2243-2248,2007.9
  25. Nakamura K, Yamagishi S, Matsui T, Yoshida T, Takenaka K, Jinnouchi Y, Yoshida Y, Ueda S, Adachi H, Imaizumi T: Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 170:2159-2170,2007
  26. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, Kitasato Y, Kawayama T, Imaizumi T, Yamada K, Young HA, Aizawa H: Pulmonary inflammation and enphysema. Role of cytokines IL-18 and IL-13. Am J Respir Crit Care Med 176:49-62,2007
  27. Saito I, Tsushima M, Sato S, Nakamura M, Kokubo Y, Mannami T, Adachi H, Konishi M, Okada K, Iso H, Kario K, Ohsuzu F, Momiyama Y: A low level of C-reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCVC- collaborative inflammation cohort (JNIC) Study. Atherosclerosis 194:238-244,2007
  28. Jinnouchi Y, Yamagishi S, Matsui T, Takenaka K, Yoshida Y, Nakamura K, Ueda S, Imaizumi T: Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice. Brain Res 1167:92-100,2007
  29. Yoshida Y, Yamagishi S, Matsui T, Nakamura K, Imaizumi T, Yoshimura K, Yamakawa R: Increased levels of pigment epithelium-derived factor in aqueous humor of patients with uveitis. Br J Ophthalmol 91:149-150,2007
  30. Yokoi M, Yamagishi S, Takeuchi M, Matsui T, Yoshida Y, Ohgami K, Amano-Okamoto T, Ohno S: Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. Br J Ophthalmol 91:397-398,2007
  31. Yoshida Y, Yamagishi S, Matsui T, Nakamura K, Imaizumi T, Yoshimura K, Yamakawa R: Positive correlation between pigment epithelium-derived factor and monocyte chemoattractant protein-1 levels in the aqueous humour of patients with uveitis. Br J Ophthalmol 91:737-738,2007
  32. Yokoi M, Yamagishi S, Saito A, Yoshida Y, Matsui T, Saito W, Hirose S, Ohgami K, Kase M, Ohno S: Positive association of pigment epithelium-derived factor with total anti-oxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 91:885-887,2007
  33. Yoshida Y, Yamagishi S, Matsui T, Nakamura K, Imaizumi T, Yoshimura K, Yamakawa R: Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy. Br J Ophthalmol 91:1133-1134,2007
  34. Kajimoto H, Hashimoto K, Bonnet SN, Haromy A, Harry G, Moudgil R, Nakanishi T, Rebeyka I, Thebaud B, Michelakis ED, Archer SL: Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: a newly recognized mechanism for sustaining ductal constriction. Circulation 115:1777-1788,2007
  35. Kajimoto H, Nakazawa M, Murasaki K, Mori Y, Tanoue K, Kasanuki H, Nakanishi T: Increased thrombogenesity in patients with cyanotic congenital heart disease. Circ J 71:948-953,2007
  36. Miyata E, Satoh S, Inokuchi K, Aso A, Kimura Y, Yokoyama S, Mori E, Nakamura T, Matsumoto M, Fujino Y, Kishihara Y, Uda K, Takemoto K, Inoue T, Nakayama S, Kobayashi R, Uesugi N, Hiyamuta K: Three fatal cases of rapidly progressive infective endocarditis caused by staphylococcus aureus. -One case with huge vegetation- Circ J 71:1488-1491,2007
  37. Sasayama S, Satoh T, Izumi T, Yoshida S, Kyotani S, Tahara N: Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients. Curr Med Res Opin 23(2):395-400,2007
  38. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T: Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 23(5):368-371,2007
  39. Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y: Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of reactive oxygen species in adipocytes. Diabetes Res Clin Prac 76:236-244,2007
  40. Menotti A, Lanti M, Kromhout D, Blackburn H, Nissinen A, Dontas A, Kafatos A, Nedeljkovic S, Adachi H: Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study. Eur J Epidemiol 22:747-754,2007
  41. Kawaguti Y, Toyomasu K, Yoshida N, Baba K, Uemoto M, Minota S: Measuring job among hospital nurses: An attempt to identify biological markers. Fukuoka Acta Medica 98(2):48-55,2007
  42. Yamagishi S, Nakamura K, Matsui T, Yoshida T, Takeuchi M, Imaizumi T: Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm Metab Res 39:233-235,2007
  43. Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K, Matsui T, Nakamura K, Imaizumi T: Serum level of advanced glycation end-products(AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 39:845-848,2007
  44. Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K, Matsuoka H, Imaizumi T, Okuda S: Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 18:1525-1533,2007
  45. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nonaka M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S: Elevated levels of serum advanced glycation end products in patients with nonalcoholic steatohepatitis. J Gastroenterology and Hepatology 22:1112-1119,2007
  46. Ihara Y, Egashira K, Nakano K, Ohtani K, Kubo M, Koga J, Iwai M, Horiuchi M, Gang Z, Yamagishi S, Sunagawa K: Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J Mol Cell Cardiology 43:455-464,2007
  47. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Takeuchi M, Inoue H, Yoshida Y, Imaizumi T: Pigment epithelium-derived factor (PEDF) suppresses expression of receptor for advanced glycation end products (RAGE) in the eye of diabetic rats. Ophthalmic Res 39:92-97,2007
  48. Yokosuka K, Park JS, Jimbo K, Yoshida T, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata K: Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro. Spine 32:E337-339,2007
  49. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Makino T, Shimizu T, Sata M: Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing reactive oxygen species generation. Vascular Disease Prevention 4:213-216,2007
  50. Kaneyuki U, Ueda S, Yamagishi S, Kato S, Fujimura T, Shibata R, Hayashida A, Yoshimura J, Kojiro M, Oshima K, Okuda S: Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascular Pharmacology 46:286-292,2007
  51. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Jinnouchi Y, Yoshida Y, Ueda S, Katsuki Y, Katsuda Y, Imaizumi T: Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis:(in press)
  52. Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, Egashira K, Matsuishi T, Kai M, Kataoka Y, Kuwano M, Imaizumi T: Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Comm:(in press)
  53. Takeshita Y, Katsuki Y, Katsuda Y, Kai H, Saito Y, Arima K, Sasaki K, Imaizumi T: Vitamin C reversed malfunction of peripheral blood-derived mononuclear cells in@smokers through antioxidant property. Circ J:(in press)
  54. Inage T, Yoshida T, Hiraki T, Ohe M, Takeuchi T, Nagamoto Y, Fukuda Y, Gondo T, Imaizumi T: Chronic cardiac resynchronization therapy reverses cardiac remodeling and improves invasive hemodynamics of patients with severe heart failure on optimal medical treatment. Europace:(in press)
  55. Ohe M, Yoshida T, Hiraki T, Matsumoto M, Otsubo H, Inage T, Imaizumi T: Detection of coronary artery stenosis after successful percutaneous coronary intervention by dipyridamole stress portable type signal-averaged electrocardiography. - A prospective study - Heart and Vessels:(in press)
  56. Fukuda Y, Yoshida T, Inage T, Takeuchi T, Nagamoto Y, Gondo T, Imaizumi T: Implantation of pacemaker for sick sinus syndrome in patient with persistent left superior vena cava and absent right superior vena cava. Heart and Vessels:(in press)
  57. Enomoto M, Adachi H, Fukami A, Furuki K, Satoh A, Otsuka M, Kumagae S, Nanjo Y, Shigetoh Y, Imaizumi T: Serum dehydroepiandrosteone sulfate levels predict longevity in men. - 27-year follow-up study in a community-based cohort (Tanushimaru study) - J Am Geriatr Soc:(in press)
  58. Honda A, Abe R, Makino T, Norisugi O, Fujita Y, Watanabe H, Nishihira J, Iwakura Y, Yamagishi S, Shimizu H, Shimizu T: Interleukin-1? and macrophage migration inhibitory factor (MIF) in dermal fibroblasts mediate UVA-induced matrix metalloproteinase-1 expression. J Dermatol Sci:(in press)
  59. Tanaka K, Ichiyama K, Hashimoto M, Yoshida H, Takimoto T, Takaesu G, Torisu T, Hanada T, Yasukawa H, Fukuyama S, Inoue H, Nakanishi Y, Kobayashi T, Yoshimura A: Loss of SOCS1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFNƒĮ on STAT3 and Smads. J Immunol:(in press)
  60. Th?baud B, Wu XC, Kajimoto H, Bonnet S, Hashimoto K, Michelakis ED, Archer SL: Developmental absence of the O2 sensitivity of L-type calcium channels in preterm ductus arteriosus smooth muscle cells impairs O2 constriction contributing to patent ductus arteriosus. Pediatr Res:(in press)
  61. Kanahara M, Kai H, Okamura T, Wada T, Suda K, Imaizumi T, Sagawa K: Usefulness of high concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high hematocrit value. Thromb Res:(in press)

˜a•¶˜_•¶

  1. Ā–ö¬–¾A‹gģˆź—mF‘å“®–¬•Ł–ŒĒ‚É‚Ø‚Æ‚élH•Ł‚Ģ‘I‘š-‹@ŠB•Ł‚©¶‘Ģ•Ł‚©- “ś–{ŠO‰ČŠw‰ļŽGŽF59-63,2007
  2. –¾Ī‰prF‹}«‘å“®–¬‰š—£. ‹~‹}ˆćŠwF379-385,2007
  3. “c’†ŒśŽõAĀ–ö¬–¾F• •”‘å“®–¬įŽ‚É‘Ī‚·‚éEndovascular aneurysm repair(EVAR). International Review of ThrombosisF54-56,2007
  4. ‘O–ģ‘׎÷C_ŒĖ‘¾˜YCœA£²ŽqC•P–ģ˜a‰ĘŽqCŠŻ–{T‘¾˜YCāĎč“c—Y‰īC“”–ģ_C{“cŒ›Ž”C—Ń—“”V‰īC–x‘å‘ C‰Ć‘ŗ•qŽ”C¼Ī–LŽŸ˜YFŽY‰ČŠO—ˆ‚Å‚Ģ‘ŁŽ™SƒGƒR[ŠO—ˆŠJŻ‚ʐę“V«SŽ¾Š³‚Ģ‘ŁŽ™f’fó‹µ. ¬Ž™zŠĀŠķŠw‰ļŽGŽF23F14-18,2007
  5. ‘O–ģ‘׎÷C‰Ŗ“cƒˆź˜YC_ŒĖ‘¾˜YCL£²ŽqC_“c@—mC“”–ģ@_CŠā“c‰¢‰īC{“cŒ›Ž”C¼Ī–LŽ”˜YF“ū—cŽ™‚ĢS‘Ÿ‚ĘSIDSD “ś–{SIDSŠw‰ļŽGŽF7F23-26,2007
  6. ‰–Œ©‰ÄŽqCŽR’†’‰‘¾˜YC“ģ•”Œõ•FC’·–å‰ėŽqC{“cŒ›Ž”CV‘ī‹³Œ°C¼‘ŗ³•FC‚‹“‘א¶C‘¾“c@–ĪFˆÓŽÆįŠQCŒÄ‹zįŠQCŠJŠį¢“ļ‚š”ŗ‚Į‚½overlap Stevens-Johnson syndrome and toxic epidermal necrolysis‚Ģ1’jŽ™—įD “V—ˆćŠw‹I—vF10i1jF94-101,2007
  7. ąV“c—Y‰FA“æ‰iŽ •FAģ—Ē•”üA‰Ķ–ģ’ŹFA‚£’J“OA¼–{‚GA—ā–““c_ŽiAX“c–ĪŽ÷FŠ„“®–¬ƒoƒCƒpƒXpŒć‚Ģ“ļŽ”«S–[×“®‚ɃtƒŒƒJƒCƒjƒh‚Ŗ’˜Œų‚µ‚½ˆź—į. ˆćŠw‚Ę–ņŠwF57:389-393,2007
  8. ŒĆ‰ź‹`‘„FŽø_‚Ģf’fEŽ”—ĆƒKƒCƒhƒ‰ƒCƒ“ 9.S‹ŲĒ Circ J@71(suppl IV): 1070-1072, 2007
  9. ’†‘ŗr”ŽA–ƒ¶–¾Œ©A—ā–““c_ŽiFƒy[ƒXƒ[ƒJ[Až‚Żp‚É‚Ø‚Æ‚é–TƒqƒX‘©ƒy[ƒVƒ“ƒO‚ĢŽŽ‚Ż. Therapeutic ResearchF28:578-582,2007
  10. ‰|–{”ü‰ĄA‘«’B@ŽõFˆź”ŹZ–Æ‚š‘ĪŪ‚Ę‚µ‚½‰uŠw“IŒ¤‹†‚©‚ēI––“œ‰»ŽY•Ø(AGEs)‚Ķ¶ŠˆKŠµ•a‚Ģi“WE—\–h‚Ģ—\’mˆöŽq‚Ę‚Č‚č“¾‚é‚©H ‘ę22‰ńŒ’Nˆć‰ČŠwŒ¤‹†•¬˜_•¶WF1-6,2007
  11. ‘«’B@ŽõF¬l•aA“Į‚É”]ESŒŒŠĒ•a‚š—\–h‚·‚éN-3ŒnŽ‰–bŽ_‚Ģ–šŠ„‚ĢŒ¤‹†. ‘ę52‰ńŽŠ‰ļŒś¶Ž–‹Ę•¬AˆćŠwŒ¤‹†•ńWF115-117,2007
  12. ‰|–{”ü‰ĄA‘«’B@ŽõFI––“œ‰»ŽY•Ø(AGEs)‚Ķ“œ”A•aE“®–¬d‰»«Ž¾Š³‚Ģi“WE—\–h‚Ģ—\’mˆöŽq‚Ę‚Č‚č“¾‚é‚©Hˆź”ŹZ–Æ‚š‘ĪŪ‚Ę‚µ‚½‰uŠw“IŒ¤‹†‚©‚ēA¶ŠˆKŠµ•a—\–h‚šŒŸ“¢ \ ‘ę22‰ńiąj‘‡Œ’N„ią’cF1-8,2007
  13. ‰|–{”ü‰ĄFPositive association of serum levels of advanced glycation end products with thrombogenic markers in humans. –¢•a‚ʍR˜V‰»F16(1):66-71,2007
  14. Ÿ“c—m•ćA’|‰ŗ‹g–¾A—L”n@Œ’AāV“”@—TAŒŽ—^Žu•vAŠOŽRN”VA²X–ŲŒ’ˆź˜YA”ņ@•×FŽ©ŒČœ‘’PŠj‹…ˆŚA‚ĘƒvƒƒXƒ^ƒOƒ‰ƒ“ƒfƒBƒ“•¹—p—Ć–@. Pharma MedicaF25F101-1042007
  15. ¼–{@ŠwA‘å‰ź‰ėMAX@—T”VAć‘ŗt•įAˆī–Ń’qmA”ņ@•×F—\–h“IICDAž‚ŻŒć5”N–Ś‚ŏ‰‚߂ĐSŽŗ×“®‚É‘Ī‚µ‚čģ“®‚µ‚½‰Ę‘°«Šg’£Œ^S‹ŲĒ‚Ģ1—į. J CardiolF(in press)
  16. ˆĄģG—YA‘åź–LŽ”A”n“nˆźŽõA”ņ@•×FS•s‘S‚Ģ•a‘Ō‚É‚Ø‚Æ‚éJAKƒVƒOƒiƒ‹§Œä‚Ģ–šŠ„A-Negative Regulation of JAK Signaling and Cardiac Injury- S‘ŸF(in press)
  17. b”ć‹vŽjA”ņ@•×F‚—p—ŹƒXƒgƒƒ“ƒOƒXƒ^ƒ`ƒ“•ž—p‚š•K—v‚Ę‚·‚é“ļŽ”«‚LDLƒRƒŒƒXƒeƒ[ƒ‹ŒŒĒ‚É‘Ī‚·‚éƒGƒ[ƒ`ƒ~ƒuŠu“ś“Š—^•¹—p—Ć–@‚Ģ—L—p«. Progress in MedicineF(in press)
  18. b”ć‹vŽjFŽ”—Ć’ļR«‚LDLƒRƒŒƒXƒeƒ[ƒ‹ŒŒĒ‚É‘Ī‚·‚éƒAƒvƒ[ƒ`. Medical PracticeF(in press)

Ē—į•ń

  1. T.Takaseya, S.Hiromatsu, H.Akashi, T.Okazaki, S.Tobinaga, S.AoyagiF A Case of@Unilateral Leg Edema Due to Abdominal Aortic Aneurysm with Aortocaval Fistula. Ann Thorac Cardiovasc SurgF135-138,2007
  2. E.Tayama, S.Chihara, S.Fukunaga, H.Akashi, S.Aoyagi, K.MizoguchiF Embolic Myocardial Infaction and Left Ventricular Rupture Due to Mital Valve Endocarditis. Ann Thorac Cardiovasc SurgF206-208,2007
  3. S.Hiromatsu, Y.Hosokawa, N.Egawa, H.Yokokura, K.Akaiwa, S.AoyagiF Strategy for isolated iliac artery@aneurysm. Asian Cardiovasc Thorac AnnF280-284,2007
  4. S.Aoyagi, S.Fukunaga, E.Tayama, E.Nakamura, N.Egawa, Y.HosokawaF Benefits of a ƒĄ-Blocker for Intractable Hemolysis due to Paraprosthetic Leakage. Asian Cardiovasc & Thorac AnnF441-443,2007
  5. S.Hiromatsu, Y.Hosokawa, N.Egawa, S.AoyagiFSpontaneous repture of the dorsalis artery : report of a case. Ann Thorac Cardiovasc SurgF290-292,2007
  6. S.Aoyagi, S.Fukunaga, E.Tayama, H.Hori, K.YoshikawaF Prosthetic valve thrombosis in the aortic position. ChirurgiaF25-28,2007
  7. Ÿ“c—m•ćA—L”n@Œ’AÖ“”@—TAŠOŽRN”VAŒŽ—^Žu•vA²X–ŲŒ’ˆź˜YA”ņ@•×FŽ©ŒČœ‘’PŠj‹…ˆŚA‚É‚ę‚édĒ‹•ŒŒŽˆ‚ĢŽ”—ƁFŽ”—ĆŒų‰Ź‚É‘Ī‚·‚é‰e‹æˆöŽq‚É‚Ā‚¢‚Ä‚ĢŒŸ“¢. –¬ŠĒŠw@47(2)F221-225,2007.4
  8. Š}Œ“–¾ŽqA“cŒ“éLAaŒūƒ~ƒmƒŠA”~ˆäG˜aA²X–ŲŒ’ˆź˜YA‚éŠģ“TAĪ‹“³•qA”ņ@•×FSƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ģf’f‚Ø‚ę‚ŃŽ”—ĆŒų‰Ź”»’č‚É18F-fluorodeoxyglucose positron emission tomography‚Ŗ—L—p‚Å‚ ‚Į‚½1—į. S‘Ÿ@39(12)F1064-1070,2007.12

‘ą

  1. Yamagishi S, Matsui T, Ueda S, Nakamura K, Imaizumi T: Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovascular & Hematological Agents in Medicinal Chemistry 5: 236-240, 2007
  2. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S: Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clinical Experimental Nephrology 11: 115-121,2007
  3. Yamagishi S, Nakamura K, Matsui T, Yoshida Y, Takenaka K, Jinnnouchi Y, Imaizumi T: Signal transduction therapy of diabetic vascular complication. Current Signal Transduction Therapy 2: 91-100,2007
  4. Fukami K, Yamagishi S, Ueda S, Okuda S: Novel therapeutic targets for diabetic nephropathy. Endocrine, Metabolic & Immune Disorders-Drug Targets 7: 83-92,2007
  5. Yamagishi S, Nakamura K, Matsui T, Ueda S, Imaizumi T: Role of postprandial hyperglycemia in cardiovascular disease in diabetes. Int J Clin Pract 61: 83-87,2007
  6. Abe R, Fujita Y, Yamagishi S: Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini-Reviews in Medicinal Chemistry 7: 649-661,2007
  7. “cŒ“éLAaŒūƒ~ƒmƒŠA”ņ@•×F18FDG-PET‚É‚ę‚é–ņ•Ø—Ć–@‚ĢŒų‰Ź”»’č. The Lipid 18(1)F71-78,2007.1
  8. āV“”@—TAŸ“c—m•ćA”ņ@•×F‹•ŒŒ«SŽ¾Š³‚Ģƒvƒ‰ƒCƒ}ƒŠƒPƒA. —Õą¬‚ĘŒ¤‹†@84(1)F7-12,2007.1
  9. ŒĆ–Ų‹v”üŽqA¼‰ŖG—mA‘«’B@ŽõA”ņ@•×FNO‡¬‘jŠQ•ØŽæADMA. zŠĀŠķ‰Č61(2)F144-151,2007.2
  10. ‘ź@Œ’Ab”ć‹vŽjA”ņ@•×FŠ„“®–¬d‰»‚ʍ‚ŒŒˆ³-Šī‘b. “®–¬d‰»—\–h6(1)F28-33,2007.4
  11. b”ć‹vŽjF“®–¬d‰»ŠwUPDATE-“®–¬d‰»‚Ģ¬‚č—§‚æ‚š—‰š‚·‚éDFDG-PET-“®–¬d‰»ƒvƒ‰[ƒN‚Ģ‰ŠĒ‚š‚Ż‚éD ˆćŠw‚Ģ‚ ‚ä‚Ż@221 (13)F1258-1262, 2007.6
  12. ²“”@WA‘å“ą“c¹’¼A”ņ@•×FANP»Ü-ƒæŒ^ƒqƒgS–[«ƒiƒgƒŠƒEƒ€—˜”Aƒyƒvƒ`ƒh»ÜihANPj‚Ģ¶—Šw“I“Į«‚Ę‹}«S•s‘S‚É‚Ø‚Æ‚éŽg—p–@. f’f‚ĘŽ”—Ć 95(10)F1751-1756,2007.10
  13. ‰|–{”ü‰ĄA”ņ@•×FƒfƒqƒhƒƒGƒsƒAƒ“ƒhƒƒXƒeƒƒ“iDHEAj‚ĘŽõ–½. ŒŸø‚Ę‹Zp@35(12)F1399-1401,2007.11
  14. —L”n@Œ’AŸ“c—m•ćA”ņ@•×FŒŒŠĒÄ¶‚Ę‹•ŒŒ«––½_ŒoįŠQ‚ĢŽ”—Ć. Heart View 11(13)F1446-1451,2007.12
  15. ¼‰ŖG—mFŽ_‰»ƒXƒgƒŒƒX. ˆćŠw‚Ģ‚ ‚ä‚Ż@“®–¬d‰»update@221:1215-1218,2007
  16. ^č’¼ŽqA–L‘Œ÷ŽŸFø_įŠQŠ³ŽŅ‚Ŗ’nˆę‚Ő¶Šˆ‚·‚邽‚ß‚ĢŽŠ‰ļŽ‘ŽæŽ‘Œ¹‚Ģ•K—v—Ź‚É‚Ā‚¢‚Ä‚ĢŒŸ“¢. ‹v—ƕĈćŠw‰ļŽGŽ@70(8)F241|248,2007
  17. ^č’¼ŽqA–L‘Œ÷ŽŸF_Œo“ļ•aŠ³ŽŅiŅ‘¬”]•Ļ«Ēj‚ĢQOL‚Ę•ŪŒ’•ŸŽƒƒT[ƒrƒX‚Ģƒj[ƒY‚ÉŠÖ‚·‚錤‹†D ‹v—ƕĈćŠw‰ļŽGŽ@70(8)F249|258,2007
  18. –L‘Œ÷ŽŸA“c’†–M–¾A‰Į“”’‰•FFƒTƒvƒŠƒƒ“ƒgŪŽę‚É‚ę‚é˜J“­ŽŅƒXƒgƒŒƒXƒ}ƒl[ƒWƒƒ“ƒg‚ĢŽŽ‚ŻD ‹v—ƕĈćŠw‰ļŽGŽ@70(8)F260|266,2007
  19. ’r“c‹v—YAŽR–{–M•FA‰Į“”GŽiA–{ŠŌ—FŠīAX“c‹±‘ćFƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚šl—¶‚µ‚½‚ŒŒˆ³Ž”—Ć‚Ģ‚ ‚č•ū. ŒŒˆ³@14:95-102,2007
  20. “cŒ“éLAaŒūƒ~ƒmƒŠA”ņ@•×F•sˆĄ’čƒvƒ‰[ƒN‚Ģ‰ę‘œf’f. ŒÄ‹z‚ʏzŠĀ Bedside Teaching@55(11):1255-1259,2007
  21. —ā–““c_ŽiFˆćŽt‚Ģ—§ź‚©‚ē‚Ż‚½Š³ŽŅ–Śü‚Ģˆć—Ć. ‘—§ˆć—ĆŠw‰ļŽˆć—Ɓ@61:473-476,2007
  22. “cŒ“éLAaŒūƒ~ƒmƒŠA”ņ •×F•ŖŽqƒCƒ[ƒWƒ“ƒO‚É‚ę‚éSŒŒŠĒ•a‚Ģf’f. THE CIRCULATION FRONTIER 11(2): 28-35,2007.6 ¼‰ŖG—mF“®–¬d‰»ƒTƒƒQ[ƒgƒ}[ƒJ[‚Ģ‚ ‚č‚©‚½. zŠĀŠķ‰Č@61:103-108,2007
  23. ’r“c‹v—YFƒAƒeƒ[ƒ€ŒŒšĒ‚Ģ•ļŠ‡“IŽ”—Ɛķ—Ŗ ŠŖ“ŖŒ¾. zŠĀŠķ‰Č@62:295-296,2007
  24. ‹g“c“TŽqA’r“c‹v—YFƒAƒeƒ[ƒ€ŒŒšĒ‚Ģ•ļŠ‡“IŽ”—Ɛķ—Ŗ ¶ŠˆKŠµ‰ü‘P‚É‚ę‚é—\–h|‰^“®—Ć–@| zŠĀŠķ‰Č@62:314-320,2007
  25. —ā–““c_ŽiFƒWƒFƒlƒŠƒbƒNˆć–ņ•i‚ĘŒö“I•a‰@‚Ģ—§ź. Ž”—Ɓ@89:561-565,2007
  26. ć“c½“ńA¼‰ŖG—mA‰œ“c½–ēFADMAFSt˜AŠÖ‚š‰š‚­V‚µ‚¢•ŖŽq•W“I. Ž”—ĆŠw@41:96-100,2007
  27. ‘ź@Œ’A‹T”ö@PA‰i“c—²MA‰i–ģ^Šģ—YAŠā‹“³lA‹Ź’u“ŽuFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Žó—e‘Ģ‘jŠQ–ņiARBj“Š—^Œć‚É‹}«t•s‘S‚š’ꂵ‚½”n’ūt‚Ģ‚PĒ—į. “ś–{“ą‰ČŠw‰ļŽGŽ@96:1195-1198,2007
  28. “c’†–M–¾A–L‘Œ÷ŽŸAŒG–{³ˆź˜YFŒy“xĮ‰»ŠĒQOL•s’²‚š‘i‚¦‚é‹Ī–±˜J“­ŽŅ‚Ö‚ĢƒTƒvƒŠƒƒ“ƒguƒŠƒZƒbƒg”üŠˆv“Š—^‚Ģ‰e‹æD “ś–{–¢•aƒVƒXƒeƒ€Šw‰ļŽ@13(1)F101|103,2007
  29. H“””ŽŽiAb”ć‹vŽjA”ņ@•×FS‹ŲƒŠƒ‚ƒfƒŠƒ“ƒOD “ś–{—Õą¬65(‘Š§)uS•s‘Sićj-ÅV‚ĢŠī‘bE—Õą¬Œ¤‹†‚Ģi•ą-v:302-306,2007
  30. b”ć‹vŽjA“cŒ“éLA”ņ@•×F“®–¬d‰»ƒvƒ‰[ƒNŠˆ“®«‚šFDG-PET‚µ‚¤‚é‚©. ”]‘²’† 29(6)F819-823,2007
  31. ŒĆ‰ź‹`‘„F‘ę11‰ńƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ļu‰‰WFS‹ŲĒ‚É‚Ø‚Æ‚éƒAƒ~ƒIƒ_ƒƒ“‚ĢŽg—pŒoŒ±. Progress in Medicine ‘Š§†@27: 848-850,2007
  32. —ā–““c_ŽiFzŠĀŠķf—Ć‚ĢÅ‘Oü. •ŖŽqŒŒŠĒ•a@8:84-89,2007
  33. b”ć‹vŽjA“cŒ“éLA”ņ@•×F“®–¬d‰»Šˆ“®«‚ĢV‚µ‚¢•]‰æ–@-FDG-PET‚É‚ę‚錟“¢- –¬ŠĒŠw 47(3)F319-325,2007
  34. Š}@O‰ĄAŒĆ‰ź‹`‘„FS‹ŲĒ‚Ģ’č‹`‚Ę•Ŗ—Ž. Medical Technology@35:1224-1228,2007
  35. ¼‰ŖG—mFŒŒ’†ƒ}[ƒJ[. Mebio@24:76-81,2007
  36. ¼‰ŖG—mFSŒŒŠĒ—Տ°ŽŽŒ±‚É‚Ø‚Æ‚éƒTƒƒQ[ƒgƒ}[ƒJ[‚É‚Ā‚¢‚Ä. —Տ°–ņ—@38:91S-92S,2007
  37. ¼‰ŖG—mAA“c^ˆź˜YA“Œ@KmA–ģoFˆźFSŒŒŠĒ•aƒTƒƒQ[ƒgƒ}[ƒJ[‚Ę‚µ‚Ä‚Ģflow-mediated vasodilation‘Ŗ’č‚Ę‚»‚Ģ•W€‰»ˆÄ. —Տ°–ņ—@38:305-309,2007

‘ŪŠw‰ļ

  1. 15th Annual Meeting of Asian Society for Cardio-Vascular Surgery, Beijing China,May 17-20,2007
    N.Egawa, S.Hiromatsu, K.Ishihara, K.Akaiwa, Y.Hosokawa, E.Nakamura, A.Tanaka,H.Akashi, S.AoyagiFEnsuring perioperative safety in patients with deep venous thrombosis by placing a nonpermanent vena cava filter prior to elective surgery.
  2. The Society for Heart Valve Disease, New York, USA,June 15-18, 2007
    S.Fukunaga, H.Hori, K.Yoshikawa, T.Ueda, E.Tayama, S.AoyagiFThe Efficacy of Combined Surgery for Chronic Atrial Fibrillation and Mitral Valve Disease.
  3. 10th Annual meeting of the Korean society of ultrasound in obstetrics and gynecology , Korea Jeju ,October.20.2007
    Maeno YFPrenatal progression of the heart disease.
  4. 10th Annual meeting of the Korean society of ultrasound in obstetrics and gynecology , Korea Jeju ,October.20.2007
    Maeno YFPrenatal management of fetal arrhythmia.
  5. Annual Meeting of the American College of the Cardiology, New Orleans, USA,March 24-27,2007
    Suda K, Kudo K, Higaki T, Nomura Y, Miura M, Matsumura M, Ayusawa M, Ogawa S, and Matsuishi TFWarfarin Treatment in Patients with Giant Coronary Aneurysms Caused by Kawasaki Disease. |A Multi-Center Study -
  6. 3rd Congress of Asian Society for Pediatric Research,Tokyo,October 6-8, 2007
    Itoh S, Suda K, Kishimoto S, Koteda Y, Ishii H, Kudo Y, Nishino H, Yoshimoto H, Mukae T, Iemura M, Matsuishi TFHomodynamic changes before and intravenous gamma globulin infusion in patients with Kawasaki syndrome.
  7. CardioRhythm 2007, Hong Kong, China, February 2-4, 2007
    Nakamura T, Aso A, Hiyamuta K: Para-Hisian Pacing for permanent pacemaker implantation in patients with normal intraventricular conduction.
  8. The 1st International Congress of Cardiomyopathies and Heart Failure (ICCHF2007), Kyoto, Japan, March 10-13, 2007
    Imaizumi T: Risk Factors of Death for Japanese HCM Patients
  9. The 1st International Congress of Cardiomyopathies and Heart Failure (ICCHF2007), Kyoto, Japan, March 10-13, 2007
    Kai H, Kudo H, Imaizumi T: Large pressure variability aggravates hypertensive cardiac remodeling- Role of perivascular inflammation-
  10. The 1st International Congress of Cardiomyopathies and Heart Failure (ICCHF2007), Kyoto, Japan, March 10-13, 2007
    Yasukawa H, Sugi Y, Fukui D, Futamata N, Kai H, Imaizumi T: Numbers of circulating dendritic cells are associated with cardiac injury and prognosis in patients with decompensated heart failure.
  11. American College of Cardiology, 56th Annual Scientific sessions, New Orleans, USA, March 24-27, 2007
    Tahara N, Mizoguchi M, Kai H, Ishibashi M, Imaizumi T: Simvastatin attenuates plaque inflammation evaluated by 18F-fluoro-2-deoxyglucose positron emission tomography.
  12. American College of Cardiology, 56th Annual Scientific sessions, New Orleans, USA, March 24-27, 2007
    Tahara N, Mizoguchi M, Kai H, Yamagishi S, Ishibashi M, Imaizumi T: Vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography is strongly associated with the metabolic syndrome.
  13. 76th Annual European Atherosclerosis Society (EAS) Congress, Helsinki, Finland, June 10-13, 2007
    Enomoto M, Adachi H, Furuki K, Kumagae S, Otsuka M, Sigetoh Y, Fukami A, Satoh A, Imaizumi T: Impact of higher blood pressure on the risk of death in 27-year follow-up study.
  14. 76th Annual European Atherosclerosis Society (EAS) Congress, Helsinki, Finland, June 10-13, 2007
    Enomoto M, Adachi H, Furuki K, Kumagae S, Otsuka M, Sigetoh Y, Fukami A, Satoh A, Imaizumi T: Serum dehydroepiandrosterone sulfate levels predict longevity men (27-year follow-up study).
  15. 76th Annual European Atherosclerosis Society (EAS) Congress, Helsinki, Finland, June 10-13, 2007
    Kumagae S, Adachi H, Enomoto M, Satoh A, Fukami A, Otsuka M, Sigetoh Y, Furuki K, Imaizumi T: TGF-ƒĄ1 is a marker for left ventricular hypertrophy in hypertensive subjects in a general population.
  16. 76th Annual European Atherosclerosis Society (EAS) Congress, Helsinki, Finland, June 10-13, 2007
    Fukami A, Adachi H, Enomoto M, Kumagae S, Otsuka M, Shigetoh Y, Furuki K, Satoh A, Imaizumi T: The association between serum monocyte chemoattractant protein-1 (MCP-1) and the metabolic syndrome.
  17. Europace 2007, Lisbon, Portugal, June 24-27, 2007
    Inage T, Yoshida T, Takeuchi T, Nagamoto Y, Gondo T, Fukuda Y, Imaizumi T: Does cardiac resynchronization therapy prevent ventricular arrhythmias?
  18. Europace 2007, Lisbon, Portugal, June 24-27, 2007
    Inage T, Yoshida T, Takeuchi T, Nagamoto Y, Fukuda Y, Gondo T,@Imaizumi T: Dual-chamber pacing induced left ventricular remodeling for severe drug@refractory symptomatic obstructive hypertrophic cardiomyopathy.
  19. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Kudo H, Kai H, Takayama N, Mori T, Takemiya K, Ikeda A, Koga M, Imaizumi T: Exaggerated blood pressure variability aggravates hypertensive cardiac remodeling through the angiotensin‡U-mediated inflammation.
  20. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Takayama N, Kai H, Kudo H, Mori T, Fukui D, Takemiya K, Ikeda A, Imaizumi T: Simvastatin attenuates cardiac hypertrophy, but not myocardial fibrosis, in spontaneously hypertensive rats with and without large blood pressure variability.
  21. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Takemiya K, Kai H, Takayama N, Tahara N, Imaizumi T: Mesenchymal stem cell-based prostacyclin synthase gene therapy for monocrotaline-induced pulmonary hypertension.
  22. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Mizuta Y, Kai H, Mizoguchi M, Imaizumi T: Valsartan attenuated myocardial fibrosis and diastolic dysfunction of hypertensive hearts in humans. Assessments using integrated backscatter analysis.
  23. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Mori T, Kai H, Takayama N, Kudo H, Takemiya K, Ikeda A, Koga M, Imaizumi T: Estrogen withdrawal prolonged vascular inflammation and oxidative stress and aggravated diastolic function in pressure-overloaded female rats.
  24. 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 17-21, 2007
    Jinnouchi Y, Yamagishi S, Takeuchi M, Imaizumi T: Atorvastatin not only decreases serum levels of AGE in diabetic patients, but also inhibits the AGE-induced C-reactive protein expression in hepatoma dendritic cells.
  25. 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 17-21, 2007
    Yoshida Y, Yamagishi S, Matsui T, Yamakawa R, Imaizumi T: Pigment epithelium-derived factor protects against AGE- or diabetes-induced retinal derangement through its anti-oxidative properties expression.
  26. Asia-Pacific Atrial Fibrillation Symposium 2007, Taipei, Taiwan, October 18-20, 2007
    Nagamoto Y, Tsuchiya T, Ashikaga K, Narita S, Gondo T, Fukuda Y, Inage T, Yoshida T, Imaizumi T: The Sagittal bundle in the right atrial appendage as a slow conduction zone or block site in the superior aspect of the reentry circuit of common atrial flutter: A study using a noncontact mapping system.
  27. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Yasukawa H, Yamamoto T, Koga M, Sugi Y, Fukui D, Futamata N, Tahara N, Kai H, Oba T, Imaizumi T: Lacking SOCS3 gene in macrophages prevents the development of atherosclerosis in ApoE deficient mice.
  28. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Arima K, Katsuda Y, Saito Y, Katsuki Y, Sasaki K, Yamagishi S, Ikeda H, Kai H, Imaizumi T: Role of PEDF in regulation of skeletal blood flow and neovascularization in ischemic limb via interaction with VEGF.
  29. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Ikeda A, Kai H, Koga M, Imaizumi T: Interferon-gamma-induced CD40/CD40 ligand pathway activation mediates atherosclerotic plaque progression and destabilization in ApoE-knockout mice.
  30. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Kudo H, Kai H, Takayama N, Mori T, Sugi Y, Fukui D, Takemiya K, Ikeda A, Koga M, Hirooka Y, Imaizumi T: Blood pressure variability-induced aggravation of end-organ damages is another achievable target of hypertension treatment. -Effects of angiotensin receptor blocker on an animal model-
  31. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Jinnouchi Y, Yamagishi S, Matsui T, Nakamura K, Takenaka K, Yoshida Y, Ueda S, Imaizumi T: Administration of pigment epithelium-derived factor inhibits cold injury-induced brain edema in mice.
  32. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Sugi Y, Yasukawa H, Kai H, Fukui D, Futamata N, Mawatari K, Ohba T, Koga M, Imaizumi T: Circulating dendritic cells may play an important role in pathophysiology in heart failure in humans.
  33. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Futamata N, Yasukawa H, Sugi Y, Kai H, Fukui D, Mawatari K, Ohba T, Tahara N, Imaizumi T: Simvastatin suppresses dendritic cell-induced autoimmune myocarditis via inhibition of dendritic cell activation.
  34. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Yasuoka S, Kudo H, Kai H, Takayama N, Mori T, Sugi Y, Fukui D, Takemiya K, Ikeda A, Koga M, Hirooka Y, Imaizumi T: Blood pressure variability-induced aggravation of end-organ damages is another achievable target of hypertension treatment. -Effects of angiotensin receptor blocker on an animal model-
  35. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Yajima T, Yasukawa H, Zhou H, Yajima T, Lim BK, Knowlton KU: Cardiac-Restricted Disruption of SOCS3 leads to dilated cardiomyopathy in a gp130 dependent manner.

‘“ąŠw‰ļ

  1. ‘ę37‰ń@“ś–{S‘ŸŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N2ŒŽ21-23“śF“Œ‹žj
    •Ÿ‰iŽüŽiA–x@‰pŽkA‹gģˆź—mA¬{‰ź’qˆźAēŒ“VŒįA“cŽR‰hŠīA–¾Ī‰prAĀ–ö¬–¾F‘m–X•Ł‘Oė•a•Ļ‚É‘Ī‚·‚éŒ`¬p‚ĢŒŸ“¢.
  2. ‘ę37‰ń@“ś–{S‘ŸŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N2ŒŽ21-23“śF“Œ‹žj
    “c’†ŒśŽõAŌŠāŒ\ˆźAĪŒ“Œ’ŽŸA”ņ‰i@ŠoA’†‘ŗ‰pŽiA×ģK•vA‰iģ‹IŽqA˜a“cŽŠOAœA¼LˆźA–¾Ī‰prAĀ–ö¬–¾F“–‰@‚É‚Ø‚Æ‚é‘å“®–¬įŽ‚É‘Ī‚·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“ą‘}p‚ĢŽ”—Ɛ¬Ńi‹Ł‹}Ē—į‚š’†S‚Ɂj
  3. ‘ę37‰ń@“ś–{S‘ŸŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N2ŒŽ21-23“śF“Œ‹žj
    ‹gģˆź—mA–x@‰pŽkA‰”‘q‹`“TAA“c’mGA•Ÿ‰iŽüŽiA“cŽR‰hŠīAēŒ“VŒįA”ö“c@‹BAŌ{WŽ”A–¾Ī‰prAĀ–ö¬–¾FŠ„“®–¬ƒoƒCƒpƒXp‚ɂ؂Ƃ鎩ŒČŒŒ—AŒŒ‚ĢŒŸ“¢.
  4. ‘ę20‰ń@“ś–{Ž©ŒČŒŒ—AŒŒŠw‰ļŠwp‘‰ļi2007”N3ŒŽ9-10“śFVŠƒj
    ‹gģˆź—mA–x@‰pŽkA‰”‘q‹`“TAA“c’mGA•Ÿ‰iŽüŽiA“cŽR‰hŠīAēŒ“VŒįA”ö“c@‹BAŌ{WŽ”A–¾Ī‰prAĀ–ö¬–¾FŠ„“®–¬ƒoƒCƒpƒXp‚ɂ؂Ƃ鎩ŒČŒŒ—AŒŒ‚ĢŒŸ“¢.
  5. ‘ę35‰ń@“ś–{ŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N5ŒŽ23-25“śF–¼ŒĆ‰®j
    ”ņ‰i@ŠoA–¾Ī‰prAœA¼LˆźA“c’†ŒśŽõAĪŒ“Œ’ŽŸA˜a“cŽŠOA‰iģ‹IŽqA×ģK•vA ’†‘ŗ‰pŽiAĀ–ö¬–¾F“–‰Č‚É‚Ø‚Æ‚é‘S‹|•”‘å“®–¬’uŠ·p?ĒšĒ–hŽ~‚Ģ‚½‚ß‚ĢH•v?
  6. ‘ę35‰ń@“ś–{ŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N5ŒŽ23-25“śF–¼ŒĆ‰®j
    “c’†ŒśŽõA‹S’Ė½“ńAŌŠāŒ\ˆźA‘å’Ė—T”VA’†‘ŗ‰pŽiA‰iģ‹IŽqAĪŒ“Œ’ŽŸAœA¼LˆźA–¾Ī‰prAĀ–ö¬–¾F• •”‘å“®–¬įŽE’°œ“®–¬įŽ‚É‘Ī‚·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒgŽ”—Ć‚Ģ‰“Šu¬Ń–ā‘č“_
  7. ‘ę35‰ń@“ś–{ŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N5ŒŽ23-25“śF–¼ŒĆ‰®j
    ‰”‘q‹`“TA“c’†ŒśŽõAŌŠāŒ\ˆźA‹S’Ė½“ńA˜a“cŽŠOAĪŒ“Œ’ŽŸAœA¼LˆźA–¾Ī‰prAĀ–ö¬–¾Fš\ŒŒ‚Å”­Ē‚µ‚½‹¹•”‘å“®–¬•a•Ļ‚É‘Ī‚·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“ą‘}pĒ—į ’†‘ŗ‰pŽiA“c’†ŒśŽõAœA¼LˆźA•Ÿ‰iŽüŽiA“cŽR‰hŠīAĪŒ“Œ’ŽŸA‹S’Ė½“ńA”ņ‰i@ŠoA ˜a“cŽŠOAŌŠāŒ\ˆźA‰iģ‹IŽqA×ģK•vA–¾Ī‰prAĀ–ö¬–¾F ŒĒ—§«’°œ“®–¬įŽ‚É‘Ī‚·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“ą‘}p
  8. ‘ę35‰ń@“ś–{ŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N5ŒŽ23-25“śF–¼ŒĆ‰®j
    ‹S’Ė½“ńA“c’†ŒśŽõAŌŠāŒ\ˆźAœA¼LˆźAĪŒ“Œ’ŽŸA”ņ‰i@ŠoA˜a“cŽŠOA‰iģ‹IŽqA×ģK•vA’†‘ŗ‰pŽiA–¾Ī‰prAĀ–ö¬–¾F‹¹•”‘å“®–¬lHŒŒŠĒ’uŠ·pŒć‚Ģ•«‡•”‰¼«įŽ‚É‘Ī‚·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“ą‘}p
  9. ‘ę35‰ń@“ś–{ŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N5ŒŽ23-25“śF–¼ŒĆ‰®j
    œA¼LˆźAĪŒ“Œ’ŽŸA‰iģ‹IŽqA×ģK•vA’†‘ŗ‰pŽiA˜a“cŽŠOA”ņ‰i@ŠoA‹S’Ė½“ńA“c’†ŒśŽõA–¾Ī‰prAĀ–ö¬–¾FˆźŽž“I‰ŗ‘åĆ–¬ƒtƒBƒ‹ƒ^[‚É‚ę‚é[•”Ć–¬ŒŒšĒ‡•¹Š³ŽŅ‚ĢŽüpŠś”xĒš—\–h
  10. ‘ę35‰ń@“ś–{ŒŒŠĒŠO‰ČŠw‰ļŠwp‘‰ļi2007”N5ŒŽ23-25“śF–¼ŒĆ‰®j
    ˜a“cŽŠOAœA¼LˆźAĪŒ“Œ’ŽŸA“c’†ŒśŽõA‰iģ‹IŽqA×ģK•vA’†‘ŗ‰pŽiAŌŠāŒ\ˆźA”ņ‰i@ŠoA–¾Ī‰prAĀ–ö¬–¾FRutherford•Ŗ—Ž‚É‚ę‚é”j—ō«• •”‘å“®–¬įŽ‚ĢŽčp¬Ń
  11. ‘ę27‰ń@“ś–{Ć–¬Šw‰ļŠwp‘‰ļi2007”N6ŒŽ18-20“śF‹ž“sj
    ‰iģ‹IŽqAœA¼LˆźA–¾Ī‰prA“c’†ŒśŽõAĪŒ“Œ’ŽŸA‹S’Ė½“ńA”ņ‰i@ŠoA˜a“cŽŠOA×ģK•vA’†‘ŗ‰pŽiAĀ–ö¬–¾F“–‰Č‚É‚Ø‚Æ‚éŽüpŠś[•”Ć–¬ŒŒšĒE”x“®–¬ĒšĒ—\–hƒ}ƒjƒ…ƒAƒ‹‚ĢŒŸ“¢
  12. ‘ę32‰ń@“ś–{ŠO‰ČŒn˜A‡Šw‰ļŠwpW‰ļi2007”N6ŒŽ22-23“śF“Œ‹žj
    “c’†ŒśŽõA‹S’Ė½“ńA”ņ‰i@ŠoA’†‘ŗ‰pŽiA×ģK•vA‰iģ‹IŽqA˜a“cŽŠOAœA¼LˆźA–¾Ī‰prAĀ–ö¬–¾F‹¹•”‘å“®–¬įŽ‚É‘Ī‚·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“ą‘}p
  13. ‘ę32‰ń@“ś–{ŠO‰ČŒn˜A‡Šw‰ļŠwpW‰ļi2007”N6ŒŽ22-23“śF“Œ‹žj
    –¾Ī‰prA•Ÿ‰iŽüŽiA“cŽR‰hŠīA”ņ‰i@ŠoAĀ–ö¬–¾F ‘å“®–¬Šī•”’uŠ·ŽčpFpŽ®‚Ę‚»‚Ģ¬Ń
  14. ‘ę13‰ń@“ś–{ŒŒŠĒ“ąŽ”—ĆŠw‰ļ‘‰ļi2007”N7ŒŽ28-29“śF“Œ‹žj
    ‹S’Ė½“ńA“c’†ŒśŽõA–¾Ī‰prAœA¼LˆźA”ņ‰i@ŠoA˜a“cŽŠOA‰iģ‹IŽqA’†‘ŗ‰pŽiA×ģK•vAĀ–ö¬–¾FStent-Graft Migration
  15. ‘ę12‰ń@“ś–{S‘ŸŒŒŠĒ–ƒŒŠw‰ļŠwp‘å‰ļi2007”N9ŒŽ15-16“śF•Ÿ‰Ŗj
    “cŽR‰hŠīFlHS”xƒ[ƒNƒVƒ‡ƒbƒvE‰ŠwŽŅ‚Ģ‚½‚ß‚ĢCPB‘•Ŗ‚©‚čuĄwIABP‚Ģ—Տ°x
  16. ‘ę60‰ń@“ś–{‹¹•”ŠO‰ČŠw‰ļ’芜ŠwpW‰ļi2007”N10ŒŽ17-20“śFå‘äj
    A“c’mGA•Ÿ‰iŽüŽiAŌ{WŽ”A¬{‰ź’qˆźAēŒ“VŒįA”ö“c@‹BA“cŽR‰hŠīAĀ–ö¬–¾F¶Žŗ‹@”\’į‰ŗ‚š”ŗ‚¤’Ā‹Œ«S‹Ų[ĒĒ—į‚É‘Ī‚·‚鍶ŽŗŒ`¬p‚ĢŒŸ“¢
  17. ‘ę60‰ń@“ś–{‹¹•”ŠO‰ČŠw‰ļ’芜ŠwpW‰ļi2007”N10ŒŽ17-20“śFå‘äj
    Ā–ö¬–¾FŠ“õ«S“ą–Œ‰Š‚ĢŽ”—Ɛķ—Ŗ
  18. ‘ę48‰ń@“ś–{–¬ŠĒŠw‰ļ‘‰ļi2007”N10ŒŽ25-27“śF¼–{j
    –¾Ī‰prA“c’†ŒśŽõA‹S’Ė½“ńA”ņ‰i@ŠoAœA¼LˆźA•Ÿ‰iŽüŽiA“cŽR‰hŠīA˜a“cŽŠOA×ģK•vA‰iģ‹IŽqA’†‘ŗ‰pŽiAŽOŠ}Œ\‘¾AĀ–ö¬–¾F ‰ŗs‘å“®–¬‚É‘Ī‚·‚鎔—Ɛķ—Ŗ
  19. ‘ę45‰ń@“ś–{lH‘ŸŠķŠw‰ļ‘å‰ļi2007”N10ŒŽ28-31“śF‘åćj
    ‹gģˆź—mA“cŽR‰hŠīA–x@‰pŽkAA“c’mGAŌ{WŽ”A”ö“c@‹BAēŒ“VŒįA•Ÿ‰iŽüŽiAĀ–ö¬–¾F“ń—t•Ł‚É‚ę‚éProsthetic valve dysfunction (PVD) ‚ĢŒŸ“¢
  20. ‘ę45‰ń@“ś–{lH‘ŸŠķŠw‰ļ‘å‰ļi2007”N10ŒŽ28-31“śF‘åćj
    H.Hori, S.Fukunaga, K.Yoshikawa, H.Akashi, S.AoyagiF Ten-year experience with the ATS open pivot bileaflet valves
  21. ‘ę69‰ń@“ś–{—Տ°ŠO‰ČˆćŠw‰ļ‘‰ļi2007”N11ŒŽ28-12ŒŽ1“śF‰”•lj
    ŽOŠ}Œ\‘¾AœA¼LˆźA‰iģ‹IŽqA’†‘ŗ‰pŽiA×ģK•vA˜a“cŽŠOA”ņ‰i@ŠoA‹S’Ė½“ńA“c’†ŒśŽõA–¾Ī‰prAĀ–ö¬–¾F“–‰Č‚É‚Ø‚Æ‚é‰ŗŽˆ•ĀĒ«“®–¬d‰»Ē‚É‘Ī‚·‚錌ŠĒ“ąŽ”—Ć‚Ģ¬Ń
  22. ‘ę9‰ń@¬lę“V«SŽ¾Š³Œ¤‹†‰ļi2007”N1ŒŽ13“śF“Œ‹žj
    ĪˆäŽ”‰ĄC{“cŒ›Ž”CH“”‰ĆŒöCˆÉ“”WˆźC¼–ģ@—TCāĎč“c—Y‰īCŠŻ–{T‘¾˜YC¼Ī–LŽŸ˜YFƒy[ƒXƒ[ƒJ[Š³ŽŅ‚Ģ”DP‚ʏoŽY Pregnancy and delivery in patients with pacemaker.
  23. ‘ę9‰ń@¬lę“V«SŽ¾Š³Œ¤‹†‰ļi2007”N1ŒŽ13“śF“Œ‹žj
    Ō–Ų’õŽ”C’†ąV@½C’O‰HŒöˆź˜YCŽĀŒ““æŽqC•P–ģ˜a‰ĘŽqF¬lę“V«SŽ¾Š³‚ĢŽŠ‰ļ“I–ā‘čG“Į‚É”DPEoŽY‚ÉŠÖ‚·‚é–ā‘č“_ Social issues of about patients with congenital heart disease : Issues of pregnancy and delivery.
  24. ‘ę9‰ń@¬lę“V«SŽ¾Š³Œ¤‹†‰ļi2007”N1ŒŽ13“śF“Œ‹žj
    ĪˆäŽ”‰ĄC{“cŒ›Ž”C•P–ģ˜a‰ĘŽqCāĎč“c—Y‰īCŠŻ–{T‘¾˜YCˆÉ“”WˆźC¼–ģ@—TC¼Ī–LŽŸ˜YF•Ŗ•ŲEoŽY‚šŒoŒ±‚µ‚½d“x‘å“®–¬•Ł‹·óŠ³ŽŅ‚Ģ‚P—į Successful pregnancy and delivery in a patient with severe valvular aortic stenosis.
  25. ‘ę9‰ń@¬lę“V«SŽ¾Š³Œ¤‹†‰ļi2007”N1ŒŽ13“śF“Œ‹žj
    ĪˆäŽ”‰ĄC{“cŒ›Ž”CŠŻ–{T‘¾˜YCāĎč“c—Y‰īCˆÉ“”WˆźC¼–ģ@—TC¼Ī–LŽŸ˜YF¬lę“V«SŽ¾Š³Š³ŽŅ‚ĢSˆö”½‰ž‚ĢŒŸ“¢ Psychogenic reaction in patients with cyanotic adult congenital heart disease.
  26. ‘ę18‰ń“ś–{Pediatric Interventional CarsiologyŒ¤‹†‰ļi2007”N1ŒŽ19“śF•Ÿ‰Ŗj
    āĎč“c—Y‰īCŠŻ–{T‘¾˜YC¼–ģ@—TCˆÉ“”WˆźCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjC‘O–ģ‘׎÷C {“cŒ›Ž”D¼Ī–LŽŸ˜YFƒRƒCƒ‹ĒšpŒć‚É”x‚ŒŒˆ³Ē‚Ģ‘ˆ«‚š”F‚ß‚½”x“®Ć–¬į‘‚Ģ15Ī’jŽ™—įD
  27. ‘ę18‰ń“ś–{Pediatric Interventional CarsiologyŒ¤‹†‰ļi2007”N1ŒŽ19“śF•Ÿ‰Ŗj
    {“cŒ›Ž”CH“”‰ĆŒöC’I¬‰Ć•¶C‘O–ģ‘׎÷CˆĄ‰i@OC‰Ę‘ŗ‘fŽjCŠŻ–{T‘¾˜YCāĎč“c—Y‰īCĪˆäŽ”‰ĄCˆÉ“”WˆźC¼–ģ@—TC¼Ī–LŽŸ˜YFS–[’†ŠuŒ‡‘¹‚É‘Ī‚·‚éƒJƒe[ƒeƒ‹Ž”—Ć‚ĘŠO‰ČŽ”—Ć‚Ģ”äŠrD
  28. ‘ę18‰ń“ś–{Pediatric Interventional CarsiologyŒ¤‹†‰ļi2007”N1ŒŽ19“śF•Ÿ‰Ŗj
    H“”‰ĆŒöC{“cŒ›Ž”C’I¬‰Ć•¶F‹É’[‚É•ĪˆŹ‚µ‚½S–[’†Šu‚É‘Ī‚µ‚āCƒJƒe[ƒeƒ‹S–[’†ŠuŒ‡‘¹ģ»p‚šs‚Į‚½”x“®–¬•Ā½Ē‚Ģ1“ūŽ™—įD
  29. ‘ę18‰ń“ś–{Pediatric Interventional CarsiologyŒ¤‹†‰ļi2007”N1ŒŽ19“śF•Ÿ‰Ŗj
    H“”‰ĆŒöC{“cŒ›Ž”C’I¬‰Ć•¶C‰Ę‘ŗ‘fŽjCˆÉ“”WˆźCĪˆäŽ”‰ĄCāĎč“c—Y‰īCŠŻ–{T‘¾˜YC¼–ģ@—TCŒj–Ų@½F“®–¬ŠĒƒRƒCƒ‹ĒšpŒć‚Ģ¶”xŒŒ—¬’į‰ŗ‚Ę”x“®–¬“ąƒRƒCƒ‹D
  30. ‘ę18‰ń“ś–{Pediatric Interventional CarsiologyŒ¤‹†‰ļi2007”N1ŒŽ19“śF•Ÿ‰Ŗj
    ŠŻ–{T‘¾˜YC{“cŒ›Ž”C¼–ģ@—TCāĎč“c—Y‰īCˆÉ“”WˆźCH“”‰ĆŒöCĪˆäŽ”‰ĄC]ćŒöNC›Œ“—mŽqC•P–ģ˜a‰ĘŽqC‰Ę‘ŗ‘fŽjC‘O–ģ‘׎÷C¼Ī–LŽŸ˜YCĀ–ö¬–¾FŠ„óĆ–¬““‚Ģ‰E–[‚Ö‚ĢŠJŒū•”•t‹ß‚ÖŒq‚Ŗ‚銄“®–¬į‘‚É‘Ī‚·‚éƒRƒCƒ‹Ēšp‚Ģ1—įD
  31. ‘ę18‰ń“ś–{Pediatric Interventional CarsiologyŒ¤‹†‰ļi2007”N1ŒŽ19“śF•Ÿ‰Ŗj
    Īˆä³_C–““cLŽĄC–Ų‘ŗƒlC’†”Ø–ķ¶C‰Ę‘ŗ‘fŽjC¬ģrˆźCˆ¼ąV@‰qC’r“c‹v—YFģč•aŒćŠ„“®–¬‹·ó•a•Ļ‚É‘Ī‚·‚éƒJƒe[ƒeƒ‹Ž”—Ć‚Ģ‰“ŠuŠś—\ŒćF‘½Ž{Ż‚É‚ę‚錟“¢D
  32. ‘ę13‰ń@“ś–{‘ŁŽ™S‘Ÿ•aŒ¤‹†‰ļi2007”N2ŒŽ10“śF‹v—ƕāj
    ‰ŗ‘ŗ’¼–ēC‘ –{ćčFC–ģX‰ŗWŽqC‰iŽRĖ‘ćC—Ń—“”V‰īC–x@‘å‘ CœA£²ŽqC‘O–ģ‘׎÷C¼Ī–LŽŸ˜YC‰Ć‘ŗ•qŽ”FŒŒŠĒ—Ö‚Ģ‘ŁŽ™SƒGƒR[‚É‚ę‚éƒXƒNƒŠ[ƒjƒ“ƒOD
  33. ‘ę13‰ń@“ś–{SIDSŠw‰ļŠwpW‰ļi2007”N3ŒŽ17“śF•Ÿ‰Ŗj
    ‘O–ģ‘׎÷Fu“ū—cŽ™“Ė‘RŽ€ĒŒóŒQ‚Ģ”­¶Œ“ˆö‚Ę—\–h-—Ž‰Ž¾Š³CŽ–ŒĢŽ€‚ā‹s‘Ņ‚Ę‚ĢŠÓ•Ź‚ąŠÜ‚ß‚Ä-v@“ū—cŽ™‚ĢS‘Ÿ‚ĘSIDSD
  34. ‘ę444‰ń@“ś–{¬Ž™‰ČŠw‰ļ•Ÿ‰Ŗ’n•ū‰ļi2007”N4ŒŽ7“śF•Ÿ‰Ŗj
    ˆäŽč‚ ‚ā‚±CŠŻ–{T‘¾˜YC{“cŒ›Ž”C¼–ģ@—TCāĎč“c—Y‰īCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjC‘O–ģ‘׎÷C¼Ī–LŽŸ˜YD‰E‘å“®–¬‹|‚šŒ_‹@‚ɐf’f‚š“¾‚½ŒŒŠĒ—Ö‚Ģ1V¶Ž™—įD
  35. ‘ę444‰ń@“ś–{¬Ž™‰ČŠw‰ļ•Ÿ‰Ŗ’n•ū‰ļi2007”N4ŒŽ7“śF•Ÿ‰Ŗj
    H“”‰ĆŒöC’I¬‰Ć•¶C{“cŒ›Ž”C‰Ę‘ŗ‘fŽjCĪˆäŽ”‰ĄCˆÉ“”WˆźCāĎč“c—Y‰īCŠŻ–{T‘¾˜YC¼–ģ@—TC¼Ī–LŽŸ˜YFAmplatzerS–[’†Šu•Ā½š‚š—p‚¢‚½S–[’†ŠuŒ‡‘¹Ē•Ā½p‚Ģ“K‰žD
  36. ‘ę18‰ń@“ś–{VƒGƒR[}Šw‰ļi2007”N4ŒŽ12“śFŒyˆä‘ņj
    ‘O–ģ‘׎÷CœA£²ŽqC•P–ģ˜a‰ĘŽqC{“cŒ›Ž”C¼Ī–LŽŸ˜YD³ķ—į‚ĢE/A”äF‘ŁŽ™—Ģˆęic’·SƒGƒR[}Šw‡TFLV torsion, E/A, Tei indexj
  37. ‘ę18‰ń@“ś–{SƒGƒR[}Šw‰ļi2007”N4ŒŽ14“śFŒyˆä‘ņj
    ĪˆäŽ”‰ĄC{“cŒ›Ž”CH“”‰ĆŒöC’rćVˆźC’I¬‰Ć•¶CāĎč“c—Y‰īCŠŻ–{T‘¾˜YCˆÉ“”WˆźC¼–ģ@—TC‰Ę‘ŗ‘fŽjC‘O–ģ‘׎÷C¼Ī–LŽŸ˜YFŒoƒJƒe[ƒeƒ‹S–[’†ŠuŒ‡‘¹•Ā½‘OŒć‚Ģ‘gDƒhƒvƒ‰–@‚É‚ę‚é—¼S‹@”\•Ļ‰»‚ĢŒŸ“¢D
  38. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    āĎč“c—Y‰īC{“cŒ›Ž”CŠŻ–{T‘¾˜YC¼–ģ@—TCˆÉ“”WˆźCH“”‰ĆŒöCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjC‘O–ģ‘׎÷C¼Ī–LŽŸ˜YFŠwZS‘ŸŒŸf‚Å”­Œ©‚³‚ź‚½Sė•””ģ‘åŒ^S‹ŲĒ‚Ģ12Ī’jŽ™—įD
  39. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    ‰Ę‘ŗ‘fŽjC_“c@—mCŒF’J—D”üC“”–ģ@_C¼Ī–LŽŸ˜YF¬Ž™‰Čˆć‚š‚Ē‚Ģ‚ꂤ‚É‘‚ā‚µ‚Ä‚¢‚­‚© `ˆćŠw•”ˆź”N¶‚É‘Ī‚·‚éEarly exposure‚ĢŽŽ‚Ż`D
  40. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    ŠŻ–{T‘¾˜YC{“cŒ›Ž”C“c’†—I•½CāĎč“c—Y‰īCĪˆäŽ”‰ĄCH“cK‘åC‰Ę‘ŗ‘fŽjC‘å•”ŒhŽOCŒĆ‰ź–õ•qC¼Ī–LŽŸ˜YF‡¬rhAcidƒæGlucosidase•ā[—Ć–@‚šs‚Į‚½Pomp•a‚Ģ‚P“ūŽ™—įD
  41. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    ĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjCŠŻ–{T‘¾˜YCāĎč“c—Y‰īCˆÉ“”WˆźC¼–ģ@—TCH“”‰ĆŒöC{“cŒ›Ž”C’†‘ŗDGC¼Ī–LŽŸ˜YFŽ©ŠoĒó‚š”ŗ‚ķ‚øŽ‘±«SŽŗ•p”‚ŖŠī–{’²—„‚Ę‚Č‚Į‚Ä‚¢‚½ˆź—įD
  42. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    ‘O–ģ‘׎÷C‰Ŗ“cƒˆź˜YC_ŒĖ‘¾˜YCœA£²ŽqC_“c@—mC“”–ģ@_C¼Ī–LŽŸ˜YF ”DPŒćŠś‚ɐf’f‚³‚ź‚½‘ŁŽ™•p”‚ĢŽüŽYŠśŠĒ—–@‚ĢŒŸ“¢F‘Ł“ąŽ”—Ć‚Ģ“K‰žD
  43. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    {“cŒ›Ž”CH“”‰ĆŒöC’I¬‰Ć•¶C‘O–ģ‘׎÷C‰Ę‘ŗ‘fŽjCĪˆäŽ”‰ĄCŠŻ–{T‘¾˜YCāĎč“c—Y‰īCˆÉ“”WˆźC¼Ī–LŽŸ˜YFS–[’†ŠuŒ‡‘¹‚É‘Ī‚·‚éƒAƒ“ƒvƒ‰ƒbƒcƒA[•Ā½š‚š—p‚¢‚½ƒJƒe[ƒeƒ‹Ž”—Ć‚ĘŠJSp‚Ģ”äŠrD
  44. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    ‘O–ģ‘׎÷CœA£²ŽqC•P–ģ˜a‰ĘŽqCŠŻ–{T‘¾˜YCāĎč“c—Y‰īCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjC{“cŒ›Ž”C‘č’¼Ž÷C¼Ī–LŽŸ˜YF–³äBĒŒóŒQ‚Ģ‘ŁŽ™f’f‚Ę—\Œć‚Ģ„’č|”xĆ–¬Œ`‘Ō‚Ę‹·ó|D
  45. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    {“cŒ›Ž”CŠŻ–{T‘¾˜YCāĎč“c—Y‰īC¼–ģ@—TCˆÉ“”WˆźCH“”‰ĆŒöCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjC¼Ī–LŽŸ˜YFģč•aŠ³ŽŅƒĮƒOƒƒuƒŠƒ“•s‰ž—į‚É‘Ī‚·‚éD’†‹…ƒGƒ‰ƒXƒ^[ƒ[‘jŠQÜ(sivelestat sodium hydrate)‚ĢŒų‰ŹD
  46. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    –““cLŽĄC{“cŒ›Ž”CˆÉ“”WˆźCāĎč“c—Y‰īCŠŻ–{T‘¾˜YCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjCĪˆä³_CćŒ“—¢’öC’†‘ŗDˆźC¼Ī–LŽŸ˜YFģč•a‘S‘’²ø‚Å•ń‚³‚ź‚½‰‰ńŽ”—ĆŒć‚Ģ‚­‚·‚Ō‚čEÄ”R—į‚ÉŠÖ‚·‚錟“¢D
  47. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    ĪˆäŽ”‰ĄC{“cŒ›Ž”CH“”‰ĆŒöC’I¬‰Ć•¶CāĎč“c—Y‰īCŠŻ–{T‘¾˜YCˆÉ“”WˆźC¼–ģ@—TC‰Ę‘ŗ‘fŽjC¼Ī–LŽŸ˜YFŒoƒJƒe[ƒeƒ‹S–[’†ŠuŒ‡‘¹•Ā½‘OŒć‚Ģ—¼S‹@”\•Ļ‰»‚Ģ‘gDƒhƒvƒ‰–@‚É‚ę‚é•]‰æD
  48. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    ĪˆäŽ”‰ĄC{“cŒ›Ž”CˆÉ“”WˆźCāĎč“c—Y‰īCŠŻ–{T‘¾˜YC¼–ģ@—TCH“”‰ĆŒöC‰Ę‘ŗ‘fŽjC¼Ī–LŽŸ˜YFŠ„“®–¬•a•Ļ‚š‚ą‚Āģč•aŠ³ŽŅ‚Ģčņ“®–¬‚Ģelastic property‚ĢŒŸ“¢D
  49. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    H“”‰ĆŒöD{“cŒ›Ž”C’I¬‰Ć•¶CˆĄ‰i@OC‰|–{’¼ŽjC¼Ī–LŽŸ˜YFƒtƒ@ƒ[Žl’„pŒćŠ³ŽŅ‚Ģćs‘å“®–¬‚ĢŠg‘å‚Ęelastic propertyD
  50. ‘ę110‰ń@“ś–{¬Ž™‰ČŠw‰ļi2007”N4ŒŽ21-22“śF‹ž“sj
    ŠŻ–{T‘¾˜YC{“cŒ›Ž”CāĎč“c—Y‰īC¼–ģ@—TCˆÉ“”WˆźCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjCH“cK‘åCŒĆ‰ź–õ•qC¼Ī–LŽŸ˜YFPompe•a‚É‘Ī‚·‚鍇¬y‘f•ā[—Ć–@‚šs‚¢2ŽŸ«S‹ŲĒ‚ʍœŠi‹Ų‹@”\‚Ģ‰ü‘P‚š“¾‚½1“ūŽ™—įD
  51. ‘ę80‰ń@“ś–{’“‰¹”gˆćŠw‰ļŠwpW‰ļi2007”N5ŒŽ18-20“śFŽ­Ž™“‡j
    ‘O–ģ‘׎÷F¬Ž™‰ČEŽY•wl‰Č@”DP’†Šś‚Ģ‘ŁŽ™ˆŁķ‚ĢƒXƒNƒŠ[ƒjƒ“ƒO@zŠĀŠķ•Ŗ–ģ‚ĢƒXƒNƒŠ[ƒjƒ“ƒO
  52. ‘ę43‰ń@“ś–{ŽüŽYŠśEV¶Ž™ˆćŠw‰ļi2007”N7ŒŽ8-10“śF“Œ‹žj
    œA£²ŽqC_ŒĖ‘¾˜YC_“c@—mC“”–ģ@_C‘O–ģ‘׎÷C‘ –{ŗFC–x@‘å‘ C‰Ć‘ŗ•qŽ”C¼Ī–LŽŸ˜YF‘ŁŽ™f’f‚µŽüŽYŠśŠĒ—‚šs‚Į‚½•Š‘¤”xĆ–¬‚ɏdĒ‹·ó‚š”ŗ‚¤–³äBĒŒóŒQ‚Ģ2Ē—įD
  53. ‘ę39‰ń@“ś–{ˆćŠw‹³ˆēi2007”N7ŒŽ27-28“śF·‰Ŗj
    ‰Ę‘ŗ‘fŽjC¼‰ŗ—D”üC“”–ģ@_C‹g‰i—zˆź˜YC–{ŠŌ^ˆźC]Œūt•FCˆäćŒŖ‹gC“ś‹g•Ū•FC“c’†’n•½C•’J@–ĪC¼Ī–LŽ”˜YF¬Ž™‰ČƒNƒŠƒjƒbƒNŽĄK‚šƒNƒŠƒjƒJƒ‹ƒNƒ‰[ƒNƒVƒbƒv‚É“±“ü‚µ‚ā`“±“üŒć5”N‚Ģ‚܂ʂ߁`
  54. ‘ę17‰ń@“ś–{ŠO—ˆ¬Ž™‰ČŠw‰ļi2007”N8ŒŽ26“śFŒF–{j
    –““cLŽĄF‹Ö‰ŒE–h‰ŒŽ‘—æ‚Ć‚­‚č‚ĢƒmƒEƒnƒED
  55. ‘ę11‰ń@ģč•aŽ”—ƍ§˜b‰ļi2007”N9ŒŽ15“śF‘åćj
    –““cLŽĄDģč•aŠ„“®–¬•a•Ļ‚Ö‚ĢƒJƒe[ƒeƒ‹Ž”—Ć‹y‚ŃŠO‰Č“IŽ”—Ć‚Ģ‰“ŠuŠś—\ŒćD
  56. ‘ę27‰ń@“ś–{ģč•aŒ¤‹†‰ļi2007”N10ŒŽ11-12“śF“Œ‹žj
    ˆÉ“”WˆźC{“cŒ›Ž”CŠŻ–{T‘¾˜YCāĎč“c—Y‰īCH“”‰ĆŒöCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjC¼Ī–LŽŸ˜YFģč•a‹¹…’™—Æ‚š‡•¹‚µ‚½2Ē—įDTwo cases of Kawasaki disease with Pleural effusion.
  57. ‘ę27‰ń@“ś–{ģč•aŒ¤‹†‰ļi2007”N10ŒŽ11-12“śF“Œ‹žj
    –““cLŽĄC{“cŒ›Ž”CˆÉ“”WˆźCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjCĪˆä³_C’†‘ŗDˆź: ģč•aŠ³ŽŅ‚Ķ‚Ē‚Ģ‚ꂤ‚ÉŽóf‚µCŽ”—Ć‚šŽó‚Æ‚Ä‚¢‚é‚©H|‘ę18‰ń‘S‘’²ø¬Ń‚š—p‚¢‚½ŒŸ“¢|DHow patients with Kawasaki disease consult the doctor and receive treatment? -From the analysis of 18th nationwide survey in Japan-.
  58. ‘ę27‰ń@“ś–{ģč•aŒ¤‹†‰ļi2007”N10ŒŽ11-12“śF“Œ‹žj
    ĪˆäŽ”‰ĄC{“cŒ›Ž”C¼–ģ@—TCāĎč“c—Y‰īCŠŻ–{T‘¾˜YCˆÉ“”WˆźC‰Ę‘ŗ‘fŽjC¼Ī–LŽŸ˜YF‘ŠO‚É‚Ä”­Ē‚µCģč•a‚ʐf’fEŽ”—Ć‚³‚ź,‹‘劄“®–¬įŽ‚šŒ`¬‚µ‚½1—įD
  59. ‘ę27‰ń@“ś–{ģč•aŒ¤‹†‰ļi2007”N10ŒŽ11-12“śF“Œ‹žj
    ]ćŒöNCāĎč“c—Y‰īCŠāŒ³“ń˜YC–““cLŽĄC{“cŒ›Ž”: ģč•aŽ”—Ć‚É‚Ø‚Æ‚é–ʉuƒOƒƒuƒŠƒ“2g/kg’P‰ń“Š—^Œć‚Ģ•s‰ž—į‚ÉŠÖ‚·‚錟“¢F”­”M‚Ę”»’f‚·‚é‘Ģ‰·‚Ę‚»‚Ģ”»’莞Šś‚É‚Ā‚¢‚āDThe examination concerning the non-responder after IVIG 2g/kg in the Kawasaki disease treatment : About fever and judgement of temperature and time.
  60. ‘ę27‰ń@“ś–{ģč•aŒ¤‹†‰ļi2007”N10ŒŽ11-12“śF“Œ‹žj
    āĎč“c—Y‰īC{“cŒ›Ž”CŠŻ–{T‘¾˜YCˆÉ“”WˆźCĪˆäŽ”‰ĄC‰Ę‘ŗ‘fŽjCH“”‰ĆŒöC]ćŒöNCŠāŒ³“ń˜YC¼Ī–LŽŸ˜Y:ƒĮƒOƒƒuƒŠƒ“•s‰ž‚Ģģč•a‚É‘Ī‚·‚éƒXƒeƒƒCƒhƒpƒ‹ƒX—Ć–@‚ĢŒŸ“¢DSreroid Pulse Therapy as the 2nd Treatment of Gamma Globurin in Kawasaki syndrome.
  61. ‘ę27‰ń@“ś–{¬Ž™zŠĀ“®‘ŌŒ¤‹†‰ļ(2007”N10ŒŽ20“śF‘åćj
    ĪˆäŽ”‰ĄD–³Ēó‚ĢS‘©Œ^S‹ŲĒ1Ē—į‚ĢŒŸ“¢D
  62. ‘ę28‰ń@“ś–{ƒAƒtƒFƒŒ[ƒVƒXŠw‰ļi2007”N11ŒŽ16-18“śF‹v—ƕāj
    ĪˆäŽ”‰ĄD‘ŠO‚É‚Ä”­Ē‚µCģč•a‚ʐf’fEŽ”—Ć‚³‚źC‹‘劄“®–¬įŽ‚šŒ`¬‚µŒŒŸ÷ŒšŠ·‚šŽ{s‚µ‚½‚PĒ—įD
  63. ‘ę52‰ń@“ś–{–¢nŽ™V¶Ž™Šw‰ļi2007”N11ŒŽ24-26“śF‚¼j
    ‘O–ģ‘׎÷CœA£²ŽqC_ŒĖ‘¾˜YC_“c@—mC“”–ģ@_C–x@‘å‘ C¼Ī–LŽŸ˜YFSŽŗ’†ŠuŒ‡‘¹Ē‚Ģo¶‘Of’f‚ĘŽüŽYŠśŠĒ—D
  64. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Roundtable Discussion 4 'Clinical Evaluation and Application of Endothelial Function' Matsuoka H, Imagism T: Assessment of endothelial function by flow-mediated vasodilatation using ultrasonography.
  65. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Featured Research Session 20 Enomoto M, Adachi H, Furuki K, Kumagae S, Otsuka M, Shigetoh Y, Fukami A, Satoh A, Imagism T: High serum dehydroepiandrosteone sulfate levels are strikingly associated with less mortality in men. (27-year follow-up study) ˆź”Ź‰‰‘č
  66. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Arima K, Katsuda Y, Saitoh Y, Katsuki Y, Sasaki K, Yamagishi S, Ikeda H, Kai H, Imagism T: Inhibition of anti-angiogenic factor, pigment epithelium-derived factor, improves ischemic angiogenesis in klotho mice.
  67. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Arima K, Katsuda Y, Saitoh Y, Katsuki Y, Sasaki K, Yamagishi S, Ikeda H, Kai H, Imagism T: Role of anti-angiogenic factor, pigment epithelium-derived factor, in VEGF-induced angiogenesis in klotho mice.
  68. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Enomoto M, Adachi H, Furuki K, Kumagae S, Otsuka M, Shigetoh Y, Fukami A, Satoh A, Imagism T: Impact of higher blood pressure on the risk of death in 27-year follow-up study.
  69. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Ohmura H, Oka N, Miyazaki H, Ueda T, Imagism T: Roles of lysyl oxidase-like protein in heart.
  70. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Katsuki Y, Sasaki K, Katsuda Y, Toyama Y, Imagism T: Neovascularization capacity of endothelial progenitor cells (EPC) in patients with Buerger's disease.
  71. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Katsuda Y, Saitoh Y, Arima K, Katsuki Y, Toyama Y, Sasaki K, Ikeda H, Imagism T: Occlusion level of limb artery predicts the efficacy of bone marrow mononuclear cell implantation for critical limb ischemia.
  72. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Kumagae S, Adachi H, Enomoto M, Fukami A, Satoh A, Shigetoh Y, Otsuka M, Furuki K, Imaizumi T: TGF-ƒĄ1 is a marker for left ventricular hypertrophy in hypertensive subjects in a general population. Saitoh Y, Sasaki K, Katsuda Y, Murohara T, Takeshita Y, Okazaki T, Arima K, Katsuki Y, Shintani S, Shimada H, Akashi H, Ikeda H, Imaizumi T: Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease.
  73. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Satoh S, Mori E, Yokoyama S, Kimura Y, Sugihara M, Ikeda S, Nakayama S, Ikeda J, Morii S, Esaki E, Aso A, Nakamura T, Matsumoto T, Hiyamuta K: Different of inflammatory markes and lymphocyte subsets at the culprit lesions between patient with stable angina and acute coronary syndromes.
  74. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Shigetoh Y, Adachi H, Enomoto M, Satoh A, Fukami A, Kumagae S, Otsuka M, Furuki K, Imaizumi T: Heart rate is a predictor for development of abnormal glucose metabolism: Prospective study for 20 years in a general population.
  75. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Jinnouchi Y, Yamagishi S, Nakamura K, Takenaka K, Ueda S, Imaizumi T: Pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice.
  76. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Sugi Y, Yasukawa H, Kai H, Fukui D, Futamata N, Koga M, Imaizumi T: Circulating dendritic cells numbers are associated with cardiac injury and prognosis in patients with decompensated heart failure.
  77. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Takayama N, Kai H, Kudoh H, Sugi Y, Fukui D, Takemiya K, Ikeda A, Yasukawa H, Imaizumi T: Effect of simvastatin and telmiartan on hypertensive cardiac remodeling by exaggerated blood pressure variability in spontaneously hypertensive rats.
  78. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Takenaka K, Yamagishi S, Nakamura K, Jinnouchi Y, Ueda S, Imaizumi T: Pigment epithelium-derived factor (PEDF) inhibits occlusive thrombus formation: Possible participation of reduced intraplatelet PEDF levels in acute coronary syndromes.
  79. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Takemiya K, Kai H, Takayama N, Mori T, Kudoh H, Ikeda A, Sugi Y, Fukui D, Futamata N, Tahara N, Yasukawa H, Imaizumi T: Mesenchymal stem cell-transplantation improves endothelial function in monocrotaline-induced pulmonary hypertension rats.
  80. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Tahara N, Mizoguchi M, Mizuta Y, Osada K, Ishibashi M, Yamagishi S, Imaizumi T: Efficacy of fasting 18F-fluorodeoxyglucose positron emission tomography for the detection of cardiac sarcoidosis.
  81. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Nakamura K, Imaizumi T, Adachi H, Jinnouchi Y, Yamagishi S, Ueda S, Takenaka K: Pigment epithelium-derived factor (PEDF) inhibits neointima formation by suppressing NADPH oxidase-mediated reactive oxygen speciesgeneration.
  82. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Fukami A, Adachi H, Furuki K, Kumagae S, Otsuka M, Shigetoh Y, Satoh A, Enomoto M, Imaizumi T: The association between serum monocyte chemoattractant protein-1 (MCP-1) and the metabolic syndrome.
  83. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Futamata N, Yasukawa H, Koga M, Fukui D, Sugi Y, Kai H, Imaizumi T: Simvastatin suppresses dendritic cell-induced autoimmune myocarditis via inhibition of dendritic cell activation.
  84. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Furuki K, Adachi H, Enomoto M, Satoh A, Fukami A, Kumagae S, Otsuka M, Matsuoka H, Ikeda H, Koga Y, Imaizumi T: Elevated plasma levels of asymmetric dimethylarginine (ADMA) and homocysteine (Hcy) are strongly associated with carotid atherosclerosis: An epidemiological study.
  85. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Matsumoto Y, Ueda S, Yamagishi S, Matsuoka H, Imaizumi T, Okuda S: Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis.
  86. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Mizuta Y, Kai H, Tahara N, Osada K, Fukui M, Imaizumi T: Valsartan attenuated myocardial fibrosis and diastolic dysfunction of hypertensive hypertrophied hearts in humans. Assessments using integrated backscatter analysis.
  87. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Mizoguchi M, Tahara N, Yamagishi S, Mizuta Y, Osada K, Ishibashi M, Imaizumi T: The disparity in the determinant factors between atherosclerosis and vascular inflammation.
  88. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Mori T, Kai H, Kudo H, Sugi Y, Takayama N, Fukui D, Ikeda A, Koga M, Yasukawa H, Imaizumi T: Prolonged enhancement of perivascular inflammation and oxidative stress aggravates hypertensive myocardial fibrosis and diastolic dysfunction in ovariectomized rats.
  89. ‘ę71‰ń@“ś–{zŠĀŠķŠw‰ļ‘‰ļEŠwpW‰ļi2007”N3ŒŽ15?17“śF_ŒĖj
    Yamamoto T, Yasukawa H, Koga M, Sugi Y, Fukui D, Futamata N, Kai H, Hoshijima M, Kataoka Y, Imaizumi T: Lacking the SOCS3 gene in macrophages prevents the development of atherosclerosis in ApoE deficient mice.
  90. ‘ę32‰ń@“ś–{”]‘²’†Šw‰ļŠwpW‰ļi2007”N3ŒŽ22?24“śF•Ÿ‰Ŗj
    ‡“ƃVƒ“ƒ|ƒWƒEƒ€‚Q "”]‘²’†‚ĢƒCƒ[ƒWƒ“ƒOFƒ}ƒNƒ‚©‚ēƒ~ƒNƒ‚Ü‚Å" b”ć‹vŽjA“cŒ“éLA”ņ •×F“®–¬d‰»ƒvƒ‰[ƒNŠˆ“®«‚šFDG-PET‚Å•]‰æ‚µ‚¤‚é‚©iµ‘Ņj
  91. ‘ę104‰ń@“ś–{“ą‰ČŠw‰ļu‰‰‰ļi2007”N4ŒŽ3`5“śF‘åćj
    ‰|–{”ü‰ĄA‘«’B@ŽõA²“”@WA[…ˆŸŽqA‘å’Ė–ƒŽ÷AŒF’JrˆźAŒĆ–Ų‹v”üŽqA”ņ@•×FŒŒ’†DHEAS’l‚Ķ’j«‚É‚Ø‚Æ‚é’·Žõ‚Ģ—\’mˆöŽq‚Å‚ ‚é\27”N‚É‚ķ‚½‚é’·Šś‘OŒü‚«Œ¤‹†‚©‚ē\
  92. ‘ę80‰ń@“ś–{ŽY‹Ę‰q¶Šw‰ļŠwpW‰ļi2007”N4ŒŽ25?28“śF‘åćj
    –L‘Œ÷ŽŸA‰Į“”’‰•FFŒ¤Cˆć‚Ģ1”NŒć‚Ģƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX‚É‹y‚Ś‚·ŠÖ˜A—vˆö‚ĢŒŸ“¢
  93. ‘ę277‰ń@“ś–{“ą‰ČŠw‰ļ‹ćB’n•ū‰ļi2007”N5ŒŽ12“śF²‰źj
    –ƒ¶–¾Œ©A’†‘ŗr”ŽA’r“cŽŸ˜YA–Ų‘ŗD–MA‰”ŽRW“ńAX@’“•vA²“”^ŽiA¼–{‚GA—ā–““c_ŽiF”­ģ«ćŽŗ«•p”Ē‚š‡•¹‚µ‚½‚“x–[ŽŗƒuƒƒbƒN‚É‘Ī‚µƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ęƒy[ƒXƒ[ƒJ[Až‚Żp‚šs‚Į‚½ˆź—į
  94. ‘ę50‰ń@“ś–{“œ”A•aŠw‰ļ”NŽŸŠwpW‰ļi2007”N5ŒŽ24?26“śFå‘äj
    w“ą—TŽqAŽRŠŻ¹ˆźA’†‘ŗ˜a¶A’|’†Ž•FAA“cWˆź˜YA¼ˆäFŒ›A’|’†³‹`A”ņ@•×FƒAƒgƒ‹ƒoƒXƒ^ƒ`ƒ“‚ĶA2Œ^“œ”A•aŠ³ŽŅ‚ɂ؂Ƃ錌’†AGEsƒŒƒxƒ‹‚š’į‰ŗ‚³‚¹‚é
  95. ‘ę50‰ń@“ś–{“œ”A•aŠw‰ļ”NŽŸŠwpW‰ļi2007”N5ŒŽ24?26“śFå‘äj
    ’|’†Ž•FAŽRŠŻ¹ˆźA’†‘ŗ˜a¶Aw“ą—TŽqAA“cWˆź˜YA¼ˆäFŒ›A’|’†³‹`A”ņ@•×FŒŒ“‰Ā—nŒ^RAGE‚ĘAGEsƒŒƒxƒ‹‚Ķ³‘ŠŠÖ‚·‚é
  96. ‘ę22‰ń@“ś–{•s®–¬Šw‰ļŠwp‘å‰ļ (2007”N5ŒŽ31“ś`6ŒŽ2“śFL“‡)
    –ƒ¶–¾Œ©A’†‘ŗr”ŽA—ā–““c_ŽiFŠO‰Č“I‚ɐS“ą–ŒƒŠ[ƒh”²‹Žp‚š•K—v‚Ę‚µ‚½ƒy[ƒXƒ[ƒJ[Až‚ŻpŒć‚Ģ“ńĒ—į
  97. ‘ę22‰ń@“ś–{•s®–¬Šw‰ļŠwp‘å‰ļ (2007”N5ŒŽ31“ś`6ŒŽ2“śFL“‡)
    Œ “”Œ’Ž÷A‹g“c‹P‹vAˆī–Ń’qmA’|“ą’qGA‰iŒ³NŽkA•Ÿ“c—TŽŸ˜YA”ņ •×F‚“x‹~‹}‹~–½ƒZƒ“ƒ^[‚Ö”Ą“ü‚³‚ź‚½–ņÜ«dĒĆ•s®–¬‚É‚Ā‚¢‚Ä‚ĢŒŸ“¢ Ž‡Œ“”ü˜aŽqA•½–Ų’B˜NFˆŁ‚Č‚é‹@˜‚ÉŠī‚Ć‚­S–[•p”‚É‘Ī‚·‚éNon-contact mapping‚š—p‚¢‚½ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“p
  98. ‘ę22‰ń@“ś–{•s®–¬Šw‰ļŠwp‘å‰ļ (2007”N5ŒŽ31“ś`6ŒŽ2“śFL“‡)
    ’|“ą’qGA‹g“c‹P‹vAˆī–Ń’qmAŒ “”Œ’Ž÷A•Ÿ“c—TŽŸ˜YA‰iŒ³NŽkA”ņ •×F–ņÜŽ”—Ć’ļR«‚Ģ‹N—§«’įŒŒˆ³‚É‘Ī‚·‚éV‚½‚ÉŠJ”­‚³‚ź‚½ƒy[ƒVƒ“ƒOƒAƒ‹ƒSƒŠƒYƒ€‚š—p‚¢Ž”—Ƃɐ¬Œ÷‚µ‚½1—į
  99. ‘ę16‰ń“ś–{SŒŒŠĒƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ļŠwpW‰ļi2007”N6ŒŽ21`23“śFŒSŽRj
    Katsuda Y, Kanaya S, Koiwaya H, Ootsuka M, Toyama Y, Arima K, Katsuki Y, Onitsuka I, Sasaki K, Takajo Y, Kai HF Early and long-term outcome of small stent: Drug eluting stent vs. Bare metal stent.
  100. ‘ę16‰ń“ś–{SŒŒŠĒƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ļŠwpW‰ļi2007”N6ŒŽ21`23“śFŒSŽRj
    Satoh S, Mori E, Yokoyama S, Kimura Y, Esaki E, Sugihara M, Nakayama S, Ikeda J, Morii S, Ikeda S, Matsumoto T, Hiyamuta K: Relationship study between coronary plaque composition and local atherogenic mediators in patients with stable angina using ultrasound radiofrequency data analysis.
  101. ‘ę16‰ń“ś–{SŒŒŠĒƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ļŠwpW‰ļi2007”N6ŒŽ21`23“śFŒSŽRj
    Yokoyama S, Mori E, Kimura Y, Sugihara M, Nakayama S, Nakamura T, Satoh S, Matsumoto T, Hiyamuta K: Clinacal outcome of sirolimus eluting stent implantation for left main trunk disease.
  102. ‘ę102‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N6ŒŽ23“śF‹{čj
    –ƒ¶–¾Œ©A’†‘ŗr”ŽAˆäćŠ°ŽqA“…’m•FA’r“cŽŸ˜YAXˆä½ŽmA’r“c^‰īA–Ų‘ŗD–MA‰”ŽRW“ńAX@’“•vA²“”^ŽiA¼–{‚GA—ā–““c_ŽiFŽø_‚šŽå‘i‚Ę‚µ‚½”­ģ«ćŽŗ«•p”Ē
  103. ‘ę102‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N6ŒŽ23“śF‹{čj
    ˆäćŠ°ŽqA²“”^ŽiA™Œ“@[A]č‰pŽiA’†ŽR@GA“…’m•FA’r“cŽŸ˜YAXˆä½ŽmA’r“c^‰īA–ƒ¶–¾Œ©A–Ų‘ŗD–MA‰”ŽRW“ńAX@’“•vA’†‘ŗr”ŽA¼–{‚GA—ā–““c_ŽiF“–‰@‚É‚Ø‚Æ‚é‹}«S‹Ų[ĒŒćS”j—ōĒ—į‚Ģ—Տ°“I”wŒi‚ĢŒŸ“¢
  104. ‘ę102‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N6ŒŽ23“śF‹{čj
    ‰Y•”‘ŽqA‚éŠģ“TA²X–ŲŒ’ˆź˜YA”~ˆäG˜aA²“”@WAÄ“”@—TA•ūŒ¦‰ĢA”Ā‰Ę’¼Ž÷Ab”ć‹vŽjA”ņ@•×F–UŒŸ‚ʼn󎀐«DŽ_‹…«S‹Ų‰Š‚Ŗ”»–¾‚µ‚½ˆź—į
  105. ‘ę102‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N6ŒŽ23“śF‹{čj
    ]č‰pŽiAŠāčŒc”üA²“”^ŽiA™Œ“@[A’†ŽR@GA–ƒ¶–¾Œ©A’r“cŽŸ˜YAXˆä½ŽmA’r“c^‰īA–Ų‘ŗD–MA‰”ŽRW“ńAX@’“•vA¼–{‚GA’†‘ŗr”ŽA—ā–““c_ŽiFS‹Ųˆķ’Ey‘f‚Ģćø‚š”F‚ß‚Č‚©‚Į‚½DŽ_‹…‘‘½Ē‚É”ŗ‚¤LoefflerS‹Ų‰ŠES–Œ‰Š‚Ģ1—į
  106. ‘ę102‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N6ŒŽ23“śF‹{čj
    •ūŒ¦‰ĢA“cŒ“éLAaŒūƒ~ƒmƒŠA”~ˆäG˜aA²X–ŲŒ’ˆź˜YA‚éŠģ“TA‰Y•”‘ŽqA™@—Y‰īAH“””ŽŽiAb”ć‹vŽjA”ņ@•×FŽķX‚Ģ”x“®–¬«‚ŒŒˆ³Ē‚É‘Ī‚·‚éƒGƒ“ƒhƒZƒŠƒ“hR–ņ‚Ģ–«Œų‰Ź
  107. ‘ę102‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N6ŒŽ23“śF‹{čj
    Ž™‹Ź‹I—mA‚éŠģ“TA²X–ŲŒ’ˆź˜YA”~ˆäG˜aA•‹{“ŽqA‹ą’J½ŽiAb”ć‹vŽjA ”ņ@•×A‰Į“”½–ēF‹}‘¬‚ÉŽlŽˆ––’[‰óŽ€‚š—ˆ‚½‚µ‚½”ē•†Œ^‘½”­Œ‹ß«“®–¬‰Š‚ʍl‚¦‚ē‚ź‚éˆź—į
  108. ‘ę102‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N6ŒŽ23“śF‹{čj
    Ž‡Œ“”ü˜aŽqA“ģžŠ‘׋PA‘ėˆä‰pˆźAŒĆ‰źĶ³A•½–Ų’B˜NFNon-contact mapping‚š—p‚¢‚Ä‚RŽķ—Ž‚ĢćŽŗ«•p”‚ĢƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ɐ¬Œ÷‚µ‚½‚P—į
  109. ‘ę7‰ń@“ś–{R‰Į—īˆćŠw‰ļ‘‰ļi2007”N7ŒŽ20`21“śF‹ž“sj
    ‰|–{”ü‰ĄA‘«’B@ŽõA[…ˆŸŽqAŒF’JrˆźA”ņ@•×FŒŒ“DHEAS‚’l‚Ķ’j«‚Å‚Ķ’·Žõ‚Ģ—\’mˆöŽq‚Å‚ ‚éA\27”NŠŌ‚Ģ‰uŠw“IŒŸ“¢\
  110. ‘ę7‰ń@“ś–{SŒŒŠĒƒJƒe[ƒeƒ‹Ž”—ĆŠw‰ļŠwpW‰ļ (2007”N8ŒŽ2?4“śF–¼ŒĆ‰®)
    Katsuki Y, Katsuda Y, Kanaya S, Ohtsuka M, Koiwaya H, Toyama Y, Arima K, Onitsuka I, Sasaki K, Takajo Y, Kai H, Imaizumi T: Long-term outcome of small stent: Sirolimus eluting stent vs Bare metal stent.
  111. ‘ę278‰ń@“ś–{“ą‰ČŠw‰ļ‹ćB’n•ū‰ļi2007”N 8ŒŽ18“śF‹v—ƕāj
    Ā–Ų—TŽiAˆī–Ń’qmA‹S’Ėˆź˜YA™@—Y‰īAˆäÆ²’mŽqAŒĆ‘‘ •¶AˆĄ‰Ŗ ˆķAw“ą—TŽqAb”ć‹vŽjA”ņ •×FdĒMRSAS“ą–Œ‰Š‚É‘Ī‚µƒy[ƒXƒ[ƒJ[ƒŠ[ƒh‚Ģ”²‹Ž‚Ŗ‘tŒų‚µ‚½ˆź—į
  112. ‘ę278‰ń@“ś–{“ą‰ČŠw‰ļ‹ćB’n•ū‰ļi2007”N 8ŒŽ18“śF‹v—ƕāj
    ˆäÆ²’mŽqA‹S’Ėˆź˜YAˆī–Ń’qmA™@—Y‰īA“cŒ“éLA’|’†Ž•FAŠāŒ³”üŽqAV“c—Ē˜aAb”ć‹vŽjA”ņ@•×F––’[”ģ‘åĒ‚É‘å“®–¬•Ł•Ā½•s‘S‚š‡•¹‚µ‚½ˆźĒ—į
  113. ‘ę4‰ń@“ś–{SŒŒŠĒƒJƒe[ƒeƒ‹Ž”—ĆŠw‰ļ‹ćB’n•ū‰ļA‘ę14‰ń“ś–{SŒŒŠĒƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ļ‹ćB’n•ū‰ļ•½¬19”N“x‹ćB‡“Æ’n•ū‰ļi2007”N8ŒŽ24`25“śFŒF–{j
    ˆäćŠ°ŽqAX@’“•vA“…’m•FA’r“cŽŸ˜YAXˆä½ŽmA’‡‹gF°A™Œ“@[A“c’†M‰pA–ƒ¶–¾Œ©AX@—²GA–Ų‘ŗD–MA‰”ŽRW“ńA’†‘ŗr”ŽA²“”^ŽiA—ā–““c_ŽiF”ē‰ŗA‚¦ž‚ŻŒ^ˆźŽž“I‰ŗ‘åĆ–¬ƒtƒBƒ‹ƒ^[‚š—p‚¢‚½[•”Ć–¬ŒŒšĒA”x“®–¬ŒŒšĒšĒ‚É‘Ī‚·‚鑁Šś—£°‚ĢŽŽ‚Ż
  114. ‘ę4‰ń@“ś–{SŒŒŠĒƒJƒe[ƒeƒ‹Ž”—ĆŠw‰ļ‹ćB’n•ū‰ļA‘ę14‰ń“ś–{SŒŒŠĒƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ļ‹ćB’n•ū‰ļ•½¬19”N“x‹ćB‡“Æ’n•ū‰ļi2007”N8ŒŽ24`25“śFŒF–{j
    ’|’†Ž•FAŸ“c—m•ćAŠOŽRN”VAŒŽ—^Žu•vA²X–ŲŒ’ˆź˜YA‹ą’J½ŽiA‹S’Ėˆź˜YA‰i“c@„A‚éŠģ“TAb”ć‹vŽjA”ņ@•×F––½•ŪŒģƒfƒBƒoƒCƒXiFiltrapj‚Ģ‰ńŽū‚Ŗ¢“ļ‚Å‚ ‚Į‚½ˆź—į
  115. ‘ę17‰ń@“ś–{”A˜HŒ‹ĪĒŠw‰ļŠwpW‰ļi2007”N8ŒŽ25“śF‹v—ƕāj
    ”ņ@•×FŽ_‰»ƒXƒgƒŒƒX‚ĶŒŒŠĒi”AŠĒHj“ą”ēŠQ‚š‚«‚½‚µŒŒŠĒi”AŠĒHj‚š‹l‚Ü‚ē‚¹‚é
  116. ‘ę11‰ń@“ś–{S•s‘SŠw‰ļŠwpW‰ļi2007”N9ŒŽ9?10“śF‰YˆĄj
    Symposium7 'Therapeutic Approach to Acute Heart Failure' Ohuchida M, Imaizumi T: The therapeutic strategy for acute heart failure: From the view point of renal protection.
  117. ‘ę11‰ń@“ś–{S•s‘SŠw‰ļŠwpW‰ļi2007”N9ŒŽ9?10“śF‰YˆĄj
    Inage T, Yoshida T, Takeuchi T, Nagamoto Y, Gondo T, Fukuda Y, Imaizumi T: Chronic cardiac resynchronization therapy reverses cardiac remodeling and improves invasive hemodynamics of patients with severe heart failure on optimal medical treatment.
  118. ‘ę11‰ń@“ś–{S•s‘SŠw‰ļŠwpW‰ļi2007”N9ŒŽ9?10“śF‰YˆĄj
    Takayama N, Kai H, Kudo H, Mori T, Sugi Y, Fukui D, Takemiya K, Ikeda A, Yasukawa H, Imaizumi T: Simvastatin attenuates the large blood pressure variability-induced cardiac hypertrophy by inhibiting ERK and Rho A.
  119. ‘ę11‰ń@“ś–{S•s‘SŠw‰ļŠwpW‰ļi2007”N9ŒŽ9?10“śF‰YˆĄj
    Mori T, Kai H, Kudo H, Takemiya K, Takayama N, Imaizumi T: Estradiol improves hypertensive myocardial fibrosis and diastolic dysfunction in ovariectomized rats by attenuating inflammatory changes.
  120. ‘ę11‰ń@“ś–{S•s‘SŠw‰ļŠwpW‰ļi2007”N9ŒŽ9?10“śF‰YˆĄj
    Yasukawa H, Sugi Y, Kai H, Imaizumi T: Numbers of circulating dendritic cells are associated with cardiac injury and prognosis in patients with decompensated heart failure.
  121. ‘ę45‰ń@‘S‘‘åŠw•ŪŒ’ŠĒ—Œ¤‹†W‰ļi2007”N10ŒŽ10?11“śF‘å•Ŗj
    –L‘Œ÷ŽŸA‰ĶŒ““cN‹MF—Žq‘åŠw¶‚É‚Ø‚Æ‚éĮ‰»ŠĒQOL•s’²‚Ę‚»‚ĢŠÖ˜A—vˆö‚É‚Ā‚¢‚Ä
  122. ‘ę45‰ń@“ś–{“œ”A•aŠw‰ļ‹ćB’n•ū‰ļi2007”N10ŒŽ12`13“śF‹{čj
    ‹“‰ir•FA¬“c•ÓCˆźA˜a“c’Ø•FA•Ÿ’J’mAŒ“@‹ÅgAœA“c—LrA’†ŽR‚Š‚Ę‚ŻA™@Œ’ŽOA’r“c‹v—YAŽR“cŒ¤‘¾˜YFƒEƒGƒXƒgŽüˆĶŒa‚Ę“ą‘ŸŽ‰–b–ŹĻ‚Ę‚ĢŠÖ˜A‚ɂ؂Ƃ鐫·‚ĢŒŸ“¢
  123. ‘ę48‰ń@“ś–{–¬ŠĒŠw‰ļ‘‰ļi2007”N10ŒŽ25“śF¼–{j
    JCAƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[‚P"ŒŒŠĒ“ą”ē‹@”\•]‰æ‚Ģ•W€‰»‚Ö‚ĢŽŽ‚Ż" ¼‰ŖG—mFŒŒŠĒ“ą”ē‹@”\•]‰æ‚Ģ—Տ°‰ž—pFFMDŒŸø‚Ģ•W€‰»
  124. ‘ę30‰ń@“ś–{‚ŒŒˆ³Šw‰ļŠwpW‰ļi2007”N10ŒŽ25?27“śF‹X–ģ˜pj
    ’r“c—–]Ab”ć‹vŽjAX@—²GA‚ŽR¬­AH“””ŽŽiAˆĄ‰Ŗ@ˆķA”ņ@•×F•ĀŒoŒć‚ŒŒˆ³«”ģ‘åSƒ‚ƒfƒ‹‚É‚Ø‚Æ‚éŠg’£įŠQ‚Ģ‹@˜-E‚QŒ‡–R‚É‚ę‚éS‹Ų“ąŒŒŠĒŽüˆĶ‰ŠĒ‚ʐS‹ŲüˆŪ‰»‚Ģ‘ˆ«-
  125. ‘ę30‰ń@“ś–{‚ŒŒˆ³Šw‰ļŠwpW‰ļi2007”N10ŒŽ25?27“śF‹X–ģ˜pj
    ‰|–{”ü‰ĄA‘«’B@ŽõA²“”@WA[…ˆŸŽqA‘å’Ė–ƒŽ÷AŒF’JrˆźAŒĆ–Ų‹v”üŽqA“ģžŠ‘׋PA”ņ@•×F‘SŽ€–S‚É‚Ē‚Ģ‰ŠĒƒ}[ƒJ[‚Ŗ—\’mˆöŽq‚Ę‚Č‚č“¾‚é‚©H ˆź”ŹZ–ÆŒŸf‚É‚Ø‚Æ‚é‚W”NŠŌ‚É‚Ø‚ę‚Ōc’fŒ¤‹†‚©‚ē\
  126. ‘ę30‰ń@“ś–{‚ŒŒˆ³Šw‰ļŠwpW‰ļi2007”N10ŒŽ25?27“śF‹X–ģ˜pj
    ŒF’JrˆźA‘«’B@ŽõA‰|–{”ü‰ĄA[…ˆŸŽqA‘å’Ė–ƒŽ÷A²“”@WAŒĆ–Ų‹v”üŽqA“ģžŠ‘׋PA”ņ@•×FŒŒŸ÷ƒGƒ“ƒhƒZƒŠƒ“-1‚Ķ‚ŒŒˆ³i“W‚Ģ—\’mˆöŽq‚ʂȂ肤‚é‚©H\ 7”NŠŌ‚Ģ’ĒÕ‰uŠwƒRƒz[ƒgŒ¤‹†‚ĢŒ‹‰Ź‚ę‚č \
  127. ‘ę30‰ń@“ś–{‚ŒŒˆ³Šw‰ļŠwpW‰ļi2007”N10ŒŽ25?27“śF‹X–ģ˜pj
    ‚ŽR¬­Ab”ć‹vŽjAX@—²GA•‹{“ŽqA’r“c—–]AˆĄ‰Ŗ@ˆķAŒĆ‰źˆņ‹vAˆĄģG—YA”ņ@•×FƒVƒ“ƒoƒXƒ^ƒ`ƒ“‚ĶŒŒˆ³•Ļ“®‚É‚ę‚éRhoA/Ras-ERKŒnŠˆ«‰»—}§‚š‰ī‚µ‚č‚ŒŒˆ³«S”ģ‘呝ˆ«‚š‰ü‘P‚·‚é[ƒXƒ^ƒ`ƒ“‚ĢV‚½‚ȐS•ŪŒģģ—p-
  128. ‘ę30‰ń@“ś–{‚ŒŒˆ³Šw‰ļŠwpW‰ļi2007”N10ŒŽ25?27“śF‹X–ģ˜pj
    […ˆŸŽqA‘«’B@ŽõA‰|–{”ü‰ĄAŒF’JrˆźA‘å’Ė–ƒŽ÷A²“”@WAŒĆ–Ų‹v”üŽqA“ģžŠ‘׋PA”ņ@•×FŒŒ“MCP-1‚ĶCardio-Renal Syndrome‚Ģkey factor‚É‚Č‚č“¾‚é‚©H@\ ˆź”ŹZ–Æ‚š‘ĪŪ‚Ę‚µ‚½‰”’f“I‰uŠwŒ¤‹†‚ę‚č\
  129. ‘ę18‰ń@“ś–{—Տ°ƒXƒ|[ƒcˆćŠw‰ļi2007”N11ŒŽ3?4“śF‘å•Ŗj
    Šā‰i“Ž‰›A–L‘Œ÷ŽŸF‘åŠw¶‚Ģƒ‰ƒCƒtƒXƒ^ƒCƒ‹‚ĘŒ’N‚É‚Ā‚¢‚Ä
  130. ‘ę22‰ń@“ś–{X”NŠśˆćŠw‰ļŠwpW‰ļi2007”N11ŒŽ17`18“śF“Œ‹žj
    ‰|–{”ü‰ĄA‘«’B@ŽõA[…ˆŸŽqAŒF’JrˆźA“ģžŠ‘׋PA”ņ@•×FŒŒ“DHEAS‚’l‚ĶA’j«‚Å‚Ķ’·Žõ‚Ģ—\’mˆöŽq‚Å‚ ‚é@\27”NŠŌ‚Ģ‰uŠw“IŒŸ“¢\
  131. ‘ę279‰ń@“ś–{“ą‰ČŠw‰ļ‹ćB’n•ū‰ļi2007”N11ŒŽ18“śF’·čj
    “ģ@’mŽqA‹S’Ėˆź˜YAˆī–Ń’qmA™@—Y‰īAŒ“Œū@„AŒĆ‘‘@•¶AŠāŒ³”üŽqA•½•ū²‹GAb”ć‹vŽjA”ņ@•×F“Į”­«‰E–[”j—ō‚É”ŗ‚¢Sƒ^ƒ“ƒ|ƒi[ƒf‚š—ˆ‚µ‚½ˆź—į
  132. ‘ę279‰ń@“ś–{“ą‰ČŠw‰ļ‹ćB’n•ū‰ļi2007”N11ŒŽ18“śF’·čj
    ‘ŗŽR‹±ŽqAˆī–Ń’qmA‹g“c‹P‹vA‹S’Ėˆź˜YA™ —Y‰īA‰iŒ³NŽkAŒ “”Œ’Ž÷A•Ÿ“c—TŽŸ˜YAb”ć‹vŽjA”ņ •×F•ĀĒ«”ģ‘åŒ^S‹ŲĒ‚É‘Ī‚·‚é DDD ƒy[ƒXƒ[ƒJŽ”—Ć‚ÉŪ‚µ‰EŽŗƒŠ[ƒh‚Ģ—Æ’uˆŹ’u‚Ę dyssynchrony ‚Ģ•]‰æ‚šs‚Į‚½ˆź—į
  133. ‘ę15‰ń@“ś–{ŒŒŠĒ¶•ØˆćŠw‰ļŠwp‘å‰ļi2007”N11ŒŽ29?30“śF•Ÿ‰Ŗj
    Kajimoto H, Kai H, Imaizumi T, Archer SLFA crucial role of Rho/Rho-kinase pathway in constriction and closure of human and rabbit ductus arteriosus. Yasukawa H, Koga M, Yamamoto T, Kai H, Imaizumi T: Macrophage-specific deletion of suppressor of cytokine signaling-3 inhibits the development of atherosclerosis in mice.
  134. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    –ƒ¶–¾Œ©A’†‘ŗr”ŽAˆäćŠ°ŽqA“…’m•FAXˆä½ŽmA’‡‹gF°AX@—²GA–Ų‘ŗD–MA‰”ŽRW“ńAX@’“•vA²“”^ŽiA—ā–““c_ŽiF–[ŽŗŚ‡•”•p”—lŠŒ©‚š”F‚ß‚½‚Ę–[ŽŗŒ‹ßƒŠƒGƒ“ƒgƒŠ[«•p”‚Ģˆź—į
  135. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    ‹ž‹ÉKŽqAX“c”Ž•FA‘ź@Œ’AŒ““c°mA‰Į“”GŽiA’r“c‹v—YAŒĆ‰ź‹`‘„F‚R‰ń–Ś‚Ģ”][ĒŒć‚É”­Œ©‚³‚ź‚½¶Žŗ“ą“ū“ŖóüˆŪ’e«Žī‚Ģˆź—į
  136. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    ćŠŌ@–²A“c’†M‰pA²“”^ŽiA’‡‹gF°A™Œ“@[A“…’m•FAˆäćŠ°ŽqA’r“cŽŸ˜YAXˆä½ŽmA–ƒ¶–¾Œ©AX@—²GA–Ų‘ŗD–MA‰”ŽRW“ńAX@’“•vA’†‘ŗr”ŽA—ā–““c_ŽiF•ĀĒ«”ģ‘åŒ^S‹ŲĒ—l‚ĢŒŒs“®‘Ō‚š’ꂵ‚½‚½‚±‚Ā‚ŚS‹ŲĒ‚Ģ1—į
  137. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    “…’m•FA‰”ŽRW“ńAˆäćŠ°ŽqA’r“cŽŸ˜YAXˆä½ŽmA’‡‹gF°A™Œ“@[A“c’†M‰pA–ƒ¶–¾Œ©AX@—²GA–Ų‘ŗD–MAX@’“•vA²“”^ŽiA’†‘ŗr”ŽA—ā–““c_ŽiFŠ„¹k‚ŖŒ“ˆö‚ʍl‚¦‚ē‚ź‚é‹}«S‹Ų[Ē‚šŒJ‚č•Ō‚µ”­Ē‚µ‚½ˆź—į
  138. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    ’m‰Ō‰prA‹S’Ėˆź˜YAˆī–Ń’qmA™@—Y‰īAŒ“Œū@„A‘ŗŽR‹±ŽqA•½•ū²‹GAŒĆ‘‘@•¶A“ģ@’mŽqAŠāŒ³”üŽqA’†‘ŗŽĄ¶AV“c—Ē˜aAĀ–Ų—TŽiAˆäÆ²’mŽqAb”ć‹vŽjA”ņ@•×F––’[”ģ‘åĒ‚É‘å“®–¬•Ł•Ā½•s‘S‚š‡•¹‚µ‚½ˆźĒ—į
  139. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    ’ĖģŠG—AŒF’J‰p‘¾A“ˆ“cŽõ•¶A‘å’Ų@mA‰i“c—²MA‹T”ö@PA‘ź@Œ’FH2 Blocker“Š—^Œć‚ɁAŠ®‘S–[ŽŗƒuƒƒbƒN‚š’ꂵ‚½‚½‚߁A‘ĢŠOŽ®ƒy[ƒXƒ[ƒJ[Ž{s‚µ‚½ˆź—į
  140. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    ’ĖģŠG—AŒF’J‰p‘¾A“ˆ“cŽõ•¶A‘å’Ų@mFįæņAšq“f‚šŽå‘i‚Ę‚µ‚½Žį”N«’ōœ“®–¬‰š—£‚Ģˆź—į
  141. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    ‰i“c—²MFH2 blocker“Š—^Œć‚ɁAŠ®‘S–[ŽŗƒuƒƒbƒN‚š’ꂵ‚½‚½‚߁A‘ĢŠOŽ®ƒy[ƒXƒ[ƒJ[Ž{s‚µ‚½ˆź—į
  142. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    V“c—Ē˜aA™@—Y‰īAĀ–Ų—TŽiAˆī–Ń’qmA‹S’Ėˆź˜YAb”ć‹vŽjA”ņ@•×FĮ‰»ŠĒoŒŒ‚É‚ę‚é•nŒŒ‚Å—U”­‚³‚ź‚½postprandial syncope‚Ģ1Ē—į
  143. ‘ę103‰ń@“ś–{zŠĀŠķŠw‰ļ‹ćB’n•ū‰ļi2007”N12ŒŽ1“śF•Ź•{j
    Œ“Œū@„A’|“ą’qGA‹g“c‹P‹vA‹S’Ėˆź˜YAˆī–Ń’qmA™@—Y‰īA‰iŒ³NŽkAŒ “”Œ’Ž÷A•Ÿ“c—TŽŸ˜YAb”ć‹vŽjA”ņ@•×F–ņÜŽ”—Ć’ļR«‚Ģ‹N—§«’įŒŒˆ³‚É‘Ī‚µ‚āAV‚½‚Čƒy[ƒVƒ“ƒOƒAƒ‹ƒSƒŠƒYƒ€‚š—p‚¢‚½1—į

Œ°²

  1. •½¬19”N“x@’¹‹’É•—ŠwpÜ
    ‘«’B@ŽõFƒƒ^ƒ{ƒŠƒbƒNĒŒóŒQ‚ĘŒŒ“”AŽ_’l‚ĢŠÖ˜A @@@@@@@\@ˆź”ŹZ–ÆŒŸf‚É‚Ø‚Æ‚é‰uŠw“IŒŸ“¢@\
  2. •½¬19”N“x@ˆä‘ŗ—Տ°Œ¤‹†§—ćÜ
    “cŒ“éLF“®–¬d‰»•a•Ļ‚ĢŠˆ“®«Ž”—ĆŒų‰Ź‚É‘Ī‚µ‚ÄFDG-PET‚š—p‚¢‚½V‚µ‚¢”»’č–@‚ĢŠJ”­
  3. ‘ę3‰ń@‚Ó‚­‚Ø‚©u—Տ°ˆćŠwŒ¤‹†Üv
    “cŒ“éLF“®–¬d‰»•a•Ļ‚ĢŠˆ“®«Ž”—ĆŒų‰Ź‚É‘Ī‚µ‚ÄFDG-PET‚š—p‚¢‚½V‚µ‚¢”»’č–@‚ĢŠJ”­
  4. ‘ę8‰ń@ƒoƒCƒGƒ‹u—Տ°ŒŒŠĒ‹@”\vŒ¤‹†•¬@—DGÜ
    aŒūƒ~ƒmƒŠFƒƒ^ƒ{ƒŠƒbƒNĒŒóŒQ‚Ķ“®–¬d‰»‚Ģ‰ŠĒ‚šŽä‹N‚·‚é[FDG-PET‚É‚ę‚錟“¢-

Œ¤‹†•¬‹ą

  1. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(‚b)
    ‘«’B@ŽõFŽ‰–b‘gD—R—ˆƒTƒCƒgƒJƒCƒ“‚ĶAƒƒ^ƒ{ƒŠƒbƒNĒŒóŒQ‚ĘŠÖ˜A‚·‚é‚©Hi140–œj
  2. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(‚b)
    ć“cWéFSŒŒŠĒŒn‚É‚Ø‚Æ‚éLysyl Oxidaseƒtƒ@ƒ~ƒŠ[‚Ģ–šŠ„i170–œj
  3. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(‚b)
    –L‘Œ÷ŽŸFˆć—Ə]Ž–ŽŅ‚É‚Ø‚Æ‚éƒe[ƒ‰[ƒ[ƒhŒ^‚ĢƒXƒgƒŒƒXƒ}ƒl[ƒWƒƒ“ƒg‚ĢŠJ”­‚É‚Ā‚¢‚āi169–œj
  4. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(‚b)
    ¼‰ŖG—mFPPARƒŠƒKƒ“ƒh‚ĢR‘½ŠjD’†‹…Šˆ«‚š‰ī‚µ‚½ŒŒŠĒ•ŪŒģģ—p‚ĢŒŸ“¢i170–œj
  5. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(‚b)
    ˆĄģG—YFƒTƒCƒgƒJƒCƒ“ƒVƒOƒiƒ‹§ŒäˆöŽqSOCS‚ĢS•s‘S‚É‚Ø‚Æ‚é–šŠ„‚Ģ‰š–¾‚ĘŽ”—Ć‚Ö‚Ģ‰ž—pi360–œj
  6. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(‚b)
    ŽRŠŻ¹ˆźFŒŒŠĒV¶—}§ģ—p‚š‚ą‚ĀF‘fć”ē—R—ˆˆöŽqƒyƒvƒ`ƒh‚Ģœ“÷ŽīŽ”—Ć‚Ö‚Ģ‰ž—pi170–œj
  7. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(‚b)
    ‹g“c“TŽqF¶ŠˆKŠµ•a‚É‚Ø‚Æ‚éŽ_‰»ƒXƒgƒŒƒX‚©‚ēŒ©‚½‰^“®‚ĢŒų‰Źi140–œj
  8. •½¬18”N“x?•½¬20”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(C)
    aŒūƒ~ƒmƒŠF‡–°Žž–³ŒÄ‹zĒŒóŒQ‚ɍ‡•¹‚·‚鍂ŒŒˆ³ES•s‘SŠ³ŽŅ‚ĢˆŁķS“d}‚ÉŠÖ‚·‚é—Տ°Œ¤‹†i100–œj
  9. •½¬19”N“x?20”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@Šī”ÕŒ¤‹†(‚b)
    b”ć‹vŽjF«·‚©‚ēŒ©‚½‚ŒŒˆ³«S‚É‚Ø‚Æ‚é‘ŸŠķįŠQ‚Ģ‹@˜‚Ģ‰š–¾i190–œj
  10. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@ŽįŽčŒ¤‹†iBj
    ’†‘ŗ˜a¶FF‘fć”ē—R—ˆˆöŽq‚É‚ę‚錌ŠĒ“ą‹·ó—}§Œų‰Ź‚ĢŒŸ“¢i170–œj
  11. •½¬18”N“x?19”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@ŽįŽčŒ¤‹†iBj
    ²X–ŲŒ’ˆź˜YFƒo[ƒWƒƒ[•a‚Ģ‹•ŒŒŽˆ‚É”F‚ß‚ē‚ź‚錌ŠĒV¶įŠQ‚ĢŠī’²‚Ę‚Č‚éƒƒJƒjƒYƒ€i130–œj
  12. •½¬19”N“x?20”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@ŽįŽčŒ¤‹†iBj
    ¼ˆäFŒ›FF‘fć”ē—R—ˆˆöŽqiPEDFj‚Ģ‰Šś“œ”A•a«–Ō–ŒĒ‚ɂ؂Ƃ錌ŠĒ“§‰ß«‚Ģ—}§i170–œj
  13. •½¬19”N“x`20”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@ŽįŽčŒ¤‹†iBj
    ‰|–{”ü‰ĄFŒŒ“NAGŠˆ«‚’l‚Ķ”]ESŒŒŠĒ•a‚Ģ—L—Ķ‚Č—\‘ŖˆöŽq‚Å‚ ‚é‚©H\’·Šś‘OŒü‚«Œ¤‹†‚ę‚č\ (190–œ)
  14. •½¬19”N“x`20”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@ŽįŽčŒ¤‹†iBj
    ‘å’Ė–ƒŽ÷F“®–¬d‰»‚ĢŽw•W‚Ę‚µ‚Ä‚ĢŠĢ×–E‘BˆöŽq‚Ģ—L—p«‚ÉŠÖ‚·‚é‰uŠw“IŒ¤‹† (170–œ)
  15. •½¬19”N“x`20”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@ŽįŽčŒ¤‹†iBj
    ²“”@WFƒŒƒ€ƒiƒ“ƒgƒŠƒ|’`”’ƒRƒŒƒXƒeƒ[ƒ‹‚ĘŒz“®–¬d‰»i“W‚Ģ‘OŒü‚«‰uŠwŒ¤‹† (200–œ)
  16. •½¬19”N“x`20”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@ŽįŽčŒ¤‹†iBj
    […ˆŸŽqFŒŒ“MCP-1‚Ķƒƒ^ƒ{ƒŠƒbƒNĒŒóŒQ‚ĘŠÖ˜A‚µ“®–¬d‰»«Ž¾Š³‚ĢŒ“ˆö‚Ę‚Č‚č“¾‚é‚©H (180–œ)
  17. •½¬19”N“x`20”N“x@•¶•”‰ČŠwČ‰ČŠwŒ¤‹†”ļ@ŽįŽčŒ¤‹†iBj
    ŒĆ–Ų‹v”üŽqF“ąˆö«NO‡¬‘jŠQ•ØŽæADMA‚ĶŒz“®–¬d‰»i“W‚Ģ—\‘ŖˆöŽq‚Ę‚Č‚č“¾‚é‚©H (240–œ)
  18. •½¬19”N“xi‘ę32‰ńj“ś–{Ž„—§ŠwZU‹»E‹¤ĻŽ–‹Ę’c@ŠwpŒ¤‹†U‹»Ž‘‹ą
    ”ņ@•×FŒŒŠĒÄ¶‚É‚ę‚é––½“®–¬•ĀĒ«Ž¾Š³Ž”—Ć-ŒŒŠĒV¶—}§ˆöŽq‚Ģ§Œä‚É‚ę‚éV‚µ‚¢Ž”—Ć-i180–œj
  19. •½¬19”N“x@Œś¶˜J“­Č‰ČŠwŒ¤‹†”ļ•ā•‹ąu“ļŽ”«Ž¾Š³Ž•žŒ¤‹†Ž–‹Ęv
    ”ņ@•×F“Į”­«S‹ŲĒ‚ÉŠÖ‚·‚é’²øŒ¤‹†”Ēi140–œj
  20. •½¬19”N“x@–Ų‘ŗ‹L”OzŠĀŠķą’cŽw’čŒ¤‹†•¬
    ”ņ@•×FŽ©ŒČœ‘×–EˆŚA‚š—p‚¢‚½AV‚µ‚¢‹•ŒŒ«––½_ŒoįŠQŽ”—Ć–@‚ĢŠJ”­i100–œj
  21. •½¬19”N“x@–Ų‘ŗ‹L”OzŠĀŠķą’cŽw’čŒ¤‹†•¬
    ”ņ@•×FŒŒŠĒ“ą”ē‘O‹ģ×–EiEPCj“€Œ‹•Ū‘¶–@‚ĢŠJ”­i100–œj
  22. •½¬19”N“x@Ī‹“ą’c•¬‹ą
    b”ć‹vŽjF‰Ā—nŒ^ƒCƒ“ƒ^[ƒtƒFƒƒ“ƒĮŽó—e‘Ģ‚š—p‚¢‚½V‚µ‚¢“®–¬d‰»Ž”—Ć‚Ģƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`|Š®‘S¶‘Ģ‹zŽūŒ^ƒR[ƒeƒBƒ“ƒOƒXƒeƒ“ƒg‚ĢŠJ”­|i1000–œj
  23. •½¬18”N“x?•½¬20”N“x ŽŌ—¼‹£‹ZŒö‰vŽ‘‹ą‹L”Oą’c S‘Ÿ•a‚Ģę‹ģ“IŒ¤‹†•¬Ž–‹Ę
    b”ć‹vŽjFS•s‘S“ļŽ”‰»‚ĢƒƒJƒjƒYƒ€‰š–¾‚ʐV‚µ‚¢Ž”—Ć–@‚ĢŠJ”­i500–œj
  24. •½¬19”N“x@Œö‰vM‘õƒ^ƒjƒ^Œ’N‘ĢdŠī‹ąŒ¤‹†•¬
    ‘«’B@ŽõFŽ‰–b×–E—R—ˆ‚ĢƒTƒCƒgƒJƒCƒ“‚ĶAƒƒ^ƒ{ƒŠƒbƒNĒŒóŒQ‚ĘŠÖ˜A‚·‚éHF”_‘ŗ‚Ø‚ę‚Ń‹™‘ŗ‚Å‚Ģˆź”ŹZ–Æ‚š‘ĪŪ‚Ę‚µ‚½‰uŠwŒ¤‹†i50–œj
  25. •½¬19”N“x@’É•—Œ¤‹†‰ļŠwpŒ¤‹†•¬
    ‘«’B@ŽõFƒƒ^ƒ{ƒŠƒbƒNĒŒóŒQ‚ĘŒŒ“”AŽ_’l‚ĢŠÖ˜A?ˆź”ŹZ–ÆŒŸf‚É‚Ø‚Æ‚é‰uŠw“IŒŸ“¢?(100–œ)
  26. ‘—§•a‰@‹@\Žå“±EBM„i‘å‹K–Ķ—Տ°Œ¤‹†
    —ā–““c _ŽiFŠ„“®–¬Ž¾Š³Ž”—Ć‚É‚Ø‚Æ‚éƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“—Ć–@‚Ģ‘Ć“–«‚É‚Ā‚¢‚Ä‚ĢŒŸ“¢i400–œj
  27. ‘—§•a‰@‹@\Žå“±EBM„i‘å‹K–Ķ—Տ°Œ¤‹†
    —ā–““c_ŽiF‹}«S‹Ų[Ē‘S‘‹¤“ÆŽ»ŠF’²ø‚É‚ę‚é—Տ°•]‰æŽw•W‚Ę‚»‚Ģ•]‰æi100–œj
  28. ‘—§•a‰@‹@\Žå“±EBM„i‘å‹K–Ķ—Տ°Œ¤‹†
    ’†‘ŗ r”ŽFS–[×“®‚É‚ę‚éSŒ“«”]Ēš—\–h‚É‚Ø‚Æ‚éRŒŒš—Ć–@‚ĢŽĄ‘Ō’²øi36–œj
  29. •½¬19”N“x@•¶•”‰ČŠwČŽŠ‰ļ˜AŒg„iŽ–‹Ę”ļ
    ŽRŠŻ¹ˆźFF‘fć”ē—R—ˆˆöŽq‚Ģ‚Ŗ‚ńE“®–¬d‰»ĒŽ”—Ć‚Ö‚Ģ‘Ī‰ži4000–œj
  30. •½¬18”N“x?•½¬20”N“x@•¶•”‰ČŠwČ”­“WŒ^“sŽsƒGƒŠƒAŽYŠwŠÆ˜AŒg‘£iŽ–‹Ę
    ŽRŠŻ¹ˆźiŒ¤‹†•Ŗ’SŽŅjFAGE‘jŠQ‹@”\«H•iŠJ”­ƒvƒƒWƒFƒNƒg
  31. ŒoĻŽY‹ĘČ@’nˆęV¶ƒRƒ“ƒ\[ƒVƒAƒ€‘no„iˆĻ‘õŒ¤‹†”ļ
    ŽRŠŻ¹ˆźF…—n«ƒGƒ‰ƒXƒ`ƒ“‚É‚ę‚éV‹K“®–¬d‰»—\–hŒ^‹@”\«H•i‚ĢŠJ”­i661,500‰~j
  32. ‘ę27‰ńi•½¬19”N“xj–Ų‘ŗ‹L”OzŠĀŠķą’cŒ¤‹†•¬
    ˆĄģG—YFS•s‘S‚Ģ”­Ē‚ʐi“W‚É‚Ø‚Æ‚éƒTƒCƒgƒJƒCƒ“ƒVƒOƒiƒ‹§ŒäˆöŽq‚Ģ–šŠ„‚Ģ‰š–¾i100–œj
  33. •½¬19”N“x@“Ę—§s­–@l ˆć–ņŠī”ÕŒ¤‹†ŠŽó‘õŒ¤‹†”ļ
    ˆĄģG—YFJAKƒ`ƒƒVƒ“ƒLƒi[ƒ[§Œä‚É‚ę‚éƒAƒŒƒ‹ƒM[E‰ŠĒ«Ž¾Š³Ž”—Ć‚ĢVķ—Ŗi500–œj
  34. ‘ę3‰ń@‚Ó‚­‚Ø‚©u—Տ°ˆćŠwŒ¤‹†Üv•¬
    “cŒ“éLF“®–¬d‰»•a•Ļ‚ĢŠˆ“®«‚ĘŽ”—ĆŒų‰Ź‚É‘Ī‚µ‚ÄFDG-PET‚š—p‚¢‚½V‚µ‚¢”»’č–@‚ĢŠJ”­ i80–œj
  35. •½¬19”N“x@Ž“c‹L”OˆćŠw–ņŠwU‹»ą’c‘ę25‰ńŒ¤‹†•¬
    ²X–ŲŒ’ˆź˜YFƒo[ƒWƒƒ[•a‚Ģ‹•ŒŒŽˆ––½‚É”F‚ß‚ē‚ź‚錌ŠĒV¶įŠQ‚ĢŠī’²‚Ę‚Č‚éƒƒJƒjƒYƒ€i100–œj
  36. •½¬19”N“x@–«Ž¾Š³EƒŠƒnƒrƒŠƒeƒCƒVƒ‡ƒ“Œ¤‹†U‹»ą’cŒ¤‹†•¬
    ‰|–{”ü‰ĄF˜V‰»‚ɉe‹æ‚š‹y‚Ś‚·ˆöŽq‚Ģ‰š–¾(100–œ)
  37. •½¬19”N“x@ē‘ć“cŒ’NŠJ”­Ž–‹Ę’c‘ę54‰ńˆćŠwŒ¤‹†•¬
    ŒF’JrˆźFƒGƒ“ƒhƒZƒŠƒ“-1‚ʍ‚ŒŒˆ³Ē‹y‚Ń“®–¬d‰»‚Ģ”­Ē„i“W‚ĢŠÖ—^‚É‚Ā‚¢‚āi7”NŠŌ‚Ģ‰uŠw“I’ĒÕ’²øj@(100–œ)
  38. ‘ę8‰ń@ƒoƒCƒGƒ‹u—Տ°ŒŒŠĒ‹@”\vŒ¤‹†•¬
    aŒūƒ~ƒmƒŠFƒƒ^ƒ{ƒŠƒbƒNĒŒóŒQ‚Ķ“®–¬d‰»‚Ģ‰ŠĒ‚šŽä‹N‚·‚é[FDG-PET‚É‚ę‚錟“¢-i50–œj
  39. •½¬19”N“x@‹{“cS‘Ÿ•aŒ¤‹†U‹»Šī‹ą
    Š–{‰p”üF“ąˆö«NO‡¬‘jŠQ•ØŽæ(ADMA)‚š‰ī‚·‚é“®–¬ŠĒŽūk‚Ģ•ŖŽq‹@\Fˆā“`Žq‰ü•Ļƒ}ƒEƒX‚š—p‚¢‚½ŒŸ“¢i100–œj

“Į‹–